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Antimalarial drugs impose strong selective pressure on Plasmodium falciparum parasite genomes and 
leave signatures of selection. The evolutionary basis of drug resistant malaria in endemic and epidemic 
settings continues to remain an ongoing scientific priority whose solution carries a significant effect 
on treatment outcomes. To understand the evolutionary changes in P. falciparum during treatment 
with ACTs, we used various approaches to test the neutral models of evolution using P. falciparum 
genomic data which were collected from Kombewa and Maseno in Kisumu, Kenya between 2013 and 
2015. The Synonymous/Non-synonymous (dN/dS) ratio was used to predict the effect of selection on 
protein coding loci of the Pfk13 gene. A logistic regression model was used to test the association 
between IC50s and the SNPs. mCSM and SDM were used to detect the effects of mutations on the 
Pfk13 gene while the PRIMO web server was used to locate the SNPs on the Kelch13 propeller 
domain. Modeller V9.1 was used to predict the structure of the Kelch 13 propeller domain and the 
Posview webserver used to predict ACT/kelch 13 interactions. Population differentiation was done 
using Microsatellite analyzer to calculate FST and customized R scripts with the relevant population 
genetics packages were used in the analysis. For samples collected in 2013, Tajima’s D genomic 
summary statistic was 4.53194, Fu & Li D* 2.13380, and Fu &Li F* 3.62142. However, in 2015 
Tajima’s D was -2.42910, Fu and Li’s D* -5.2712, and Fu and Li’s F* -5.0045. The dN/dS in 2013 
was 1.0299, while in 2015 dN/dS was 2.6884. Kenyan P. falciparum SNPs occur on the intra or inter 
blade domains on the PfK13 propeller domain. The FST analysis showed minimal population 
differentiation of the parasites during treatment. There was no significant association between SNPs 
and IC50 values but SNPs at codon D547E showed association with Artesunate and D559E with AQ 
and MQ IC50 respectively. Even though there is an exponential increase in the number of non-
synonymous point mutations in the Pfk13 gene, the Kenyan P. falciparum strains remain sensitive to 
ACT drugs. Further research needs to be done by deep sequencing this location of chromosome 13 as 
it will provide more power for finding novel SNPs for further validation.  
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Chapter 1. INTRODUCTION 
1.1 Malaria History  
The term malaria was coined from the Italian word mal’aria meaning “bad air” and it has been around 
for more than four millennia before being fully discovered and understood.  Malaria is postulated to 
have influenced human populations and history (Gardner et al. 2011) and caused many deaths  in the 
ancient world (Sallares, Bouwman, and Anderung 2012). Malaria manifestation in ancient times was 
attributed to the supernatural influences among the people (Neghina et al. 2010). According to 
Hippocratic medicine, transmission of the infectious disease and the intermittent fevers were caused 
by “bad air” and “bad” water of marshes which produces Miasmata and was  thought to be affecting 
people residing around those regions (Coluzzi and Corbellini 1995). In 400 BCE, Hippocrates 
described the features of malaria and discovered its correlation with the season, with the highest 
incidences in summer (Hempelmann and Krafts 2013). Hippocrates, then drew a correlation between 
stagnant water and the malaria outbreak in the ancient Roman empire and this prompted the Romans 
to drain all the stagnant waters to help in the control of malaria  (Hempelmann and Krafts 2013). 
Historically the spread of malaria was promoted by the movement of migrants, long distance traders 
and conquering forces (Roper et al. 2004; Tatem, Rogers, and Hay 2006). As late as the sixteenth 
century to the early nineteenth century, major plantation were being built in Europe and this resulted 
in the slave trade which saw many Africans being transported to the new world to offer cheap labor 
(Bianchine and Russo 1992). This resulted in the death of millions of Africans and the spread of 
malaria to Europe (Bianchine and Russo 1992; Curtin 1968). The infectious diseases that were known 
to affect the Americans were smallpox, measles, and typhoid. Tropical ecosystems of the world 
provide a conducive environment for the survival and spread of malaria to other parts of the world and 
this caused the resurgence of malaria in America due to the transportation of the slaves from Africa to 
the United States of America (USA) (Bianchine and Russo 1992; Deane 1986). 
The understanding of the malaria biology and etiology has evolved over time from theories and myths 
to a clear scientific understanding due to groundbreaking advances in scientific discoveries and 
advancement in the field of medicine. In the 19th century, Marcus Terentius Varro, a Roman scholar, 
and writer discovered that mosquitoes were the vectors for malaria transmission (Hempelmann and 
Krafts 2013). Varro’s finding was later supported by Albert Freeman, an American Physician who 
later came up with nineteen proofs that showed mosquito to be the vector responsible for malaria 




doctor became the first scientist to observe malaria parasite (CDC 2012a; Hempelmann and Krafts 
2013). Bartolomeo Camillo Golgi, between 1885-1892 studied the asexual life cycle of malaria and 
came to the conclusion that there exist two forms of disease; and this was associated with two forms 
of recurring fevers, tertian and quartan which were caused by different species of Plasmodium (CDC 
2012a; Hempelmann and Krafts 2013). A groundbreaking discovery was later made in 1898 by 
Giovanni Battista Grassi, who discovered Anopheles claviger as the vector of malaria transmission 
from infected to uninfected patients (Hempelmann and Krafts 2013). Plasmodium falciparum remains 
the most lethal malarial parasite known to infect human beings and it has been doing so for more than 
two Millenia, though its origin and evolutionary history remain a controversial debate. Some studies 
suggest that malaria has its origin from gorillas and not humans, and because of the widespread 
occurrence of these Plasmodium species in Apes, they were spread to human from apes (Liu et al. 
2010). Immunochromatographic and immunohistochemical studies on certain body organs of 
mummies such as the skin and muscles have been used to demonstrate the presence of Plasmodium 
falciparum infection in Egyptian mummy remains dating back to thousands of years ago (Bianucci et 
al. 2008). The main parasites species in the genus Plasmodium that infect human beings are: P. 
malariae, P. falciparum, P. vivax, P. ovale, and P. knowlesi with P. falciparum being the most virulent 
malaria parasite and causing the highest malaria cases in the tropical settings of the world (CDC 2012b; 
Cox 2010). P. falciparum it remains a very important parasite in the study of malaria elimination in 
Africa and in the tropical regions of the world (Hay et al. 2009; Molina-Cruz et al. 2016; Snow 2015). 
 
1.2.0 Malaria Epidemiology 
Malaria is a parasitic disease transmitted by the female anopheles mosquito and it remains the most 
lethal parasitic diseases infecting and affecting humans living in the tropical locations of the world 
(Oyebola et al. 2017). Those suffering from the disease are mostly children below the age of five years 
and pregnant women (Molina-Cruz et al. 2016; Talisuna, Bloland, and D’Alessandro 2004). In Africa, 
90% of the reported cases were from young children below the age of 5 years (World Health 
Organization 2015). Malaria transmission is very intense in the tropical region of Africa which has a 
higher rate of malaria inoculation resulting in high malaria incidences (Figure 1). Approximately 216, 
million incidences of malaria were reported in the year 2017 and despite the continued efforts, 5 
million more deaths were recorded in 2017 compared with 2016 report with about 21.06% of these 
cases resulting in deaths worldwide (WHO 2017). The highest proportion of malaria infections 
occurred in resource constrained countries, according to the WHO World Malaria report, 2017. 
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Malaria infection, being a parasitic disease and its causative agent is known to be Plasmodium (Cox 
2010; Karuri and Snow 2016).  
1.2.1 Evolution of the Plasmodium falciparum  
The evolutionary time scale shows that human P.  falciparum is a close relative to the chimpanzee 
Plasmodium reichenowi parasite (Hume, Lyons, and Day 2003). These parasites are thought to have 
undergone divergence between 5 to7 million years ago, which is the time humans and chimpanzees 
are believed to have diverged from each other (Molina-Cruz et al. 2016). In phylogenetic analysis, 
these two parasites always cluster together in space when compared with other human malaria 
parasite species. Clustering together of these parasites during phylogenetic analysis show that P. 
falciparum has infected Homo sapiens sapiens for thousands of years and is as old as human history, 
however, the origin and spread of malaria parasites is still a debate (Schoepflin et al. 2008). 
Even though the evolutionary path of P. falciparum is still not clear, development of bioinformatics 
tools enables us to understand its evolutionary dynamics experimentally. Two different theories 
explain the evolution of ancient P. falciparum because of coalescent analysis of P. falciparum 
genomic sequences (Molina-Cruz et al. 2016). The first argument asserts that the absence of 
synonymous mutations in certain genes and absence of SNPs in regularly expressed genes (Hume, 
Et al.2003) shows a recent expansion of P. falciparum parasites (Schoepflin et al. 2008) and that 
positive selection can be used to explain diversity. The other camp argues that P. falciparum is 
ancient because of high polymorphism rates observed in certain genes (Hume, et al.2003). Thus, P. 
falciparum genetic sequence data provides conflicting explanations in relation to the natural or 
artificial evolution of the parasite due to drug pressure highlighting the need for further research. 
P. falciparum is believed to have originated from Africa and later spread to other continents due to 
human migration (Molina-Cruz et al. 2016; Tatem, Rogers, and Hay 2006). In the process of 
movement, P. falciparum was confronted by different species of mosquito vectors, which were 
evolutionary different from the African mosquitos (Hay et al. 2009; Neghina et al. 2010; Tatem, 
Rogers, and Hay 2006). P. falciparum parasites that were fit and had the potential of surviving in the 
local mosquito vectors continued to infect new hosts and they became fully adapted to new geographic 
locations (Molina-Cruz et al. 2016; Neghina et al. 2010). Today, approximately 70 anopheline 
mosquito vector species are known to actively transmit malaria around the globe (Hay et al. 2009; 
Sinka et al. 2012; Molina-Cruz et al. 2016). Coevolution among organisms has been suggested to have 
an influence on evolution and adaptation of other organisms in time and space during the evolutionary 
course (Molina-Cruz et al. 2016). The unique life cycles of the Plasmodium parasite and its 
antagonistic association with the human host has been shown by use of molecular markers both in the 
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host and Plasmodium genome (Molina-Cruz et al. 2016; Schoepflin et al. 2008; Frank Hawking, 
Wilson, and Gammage 1971). 
There is enough evidence showing that the human (host) immune system is the main driver of P. 
falciparum selection as shown by higher diversity in the merozoite surface protein 1 (msp1) and 
merozoite surface protein 2 (msp2), respectively, which undergo antigenic shift during the life cycle 
of the P. falciparum within the human host, enabling the parasites to evade the host immune system 
(Figure 2) (Molina-Cruz et al. 2016; Frank Hawking, Wilson, and Gammage 1971). The var genes 
in P. falciparum are highly diverse and this diversity is due to reorganization and duplication of genes 
generating multiple domains. Sixty unique var genes have been shown to be present in the P. 
falciparum genome (Lusingu and Von Seidlein 2008), and they demonstrate an extremely high level 
of diversity enabling P. falciparum to have a specific repertoire of these gene products even in a 
population of the same parasites (Molina-Cruz et al. 2016; Lusingu and Von Seidlein 2008). Every 
recombination event of this gene results in the formation of a unique var molecule due to a high 
evolution rate. Differential expression of these var genes at different time points during infection also 
enables P.  falciparum to evade the host immune system, thus increasing its chance of survival and 
continuation to infect new erythrocytes within the host (F. Hawking, Worms, and Gammage 19). It 
is evident that malaria acts as the main driver of selection for certain genetic traits in human 
populations such as alpha-thalassemia, beta-thalassemia, sickle cell anemia and other 
haemoglobinopathies in individuals living in high transmission settings (Taylor, Parobek, and 
Fairhurst 2012), and it is evident that these traits offer protection against severe malaria in these 
individuals (Molina-Cruz et al. 2016). However, it has not been determined whether the anopheline 
immune system imposes selection on P. falciparum parasites or whether the Plasmodium impose 
selection in the anopheline mosquito. If a parasite vector (Anopheles gambiae) from a high 
transmission region is infected with P. falciparum infecting human hosts from the same region 
(endemic area), the mosquito’s immune system does not illicit an optimal antiplasmodial immune 
response (Taylor, Parobek, and Fairhurst 2012; Molina-Cruz et al. 2016). This suggests that 
transmission of malaria is passive. These findings may be accurate but their interpretation might not 
be correct. This is because different researched have not come up with a single conclusion and further 
work need to be done using more advanced bioinformatics tools to further validate their findings.  
 
1.2.2 Single Nucleotide Polymorphisms and adaptive evolution  
Most of the molecular markers associated to antimalarial drug resistance are now well understood 
even though some are yet to be discovered (Picot et al. 2009). Non-synonymous single nucleotide 
polymorphisms are the main molecular markers responsible for the adaptive evolution to antimalarial 
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drug resistance in P. falciparum. For instance, SNPs at codon position: 86, 184, 1034, 1042, and 1246 
in the Pfmdr-1 gene have been shown to modulate the sensitivity of P. falciparum to chloroquine and 
Mefloquine (Foote et al. 1990). Discoveries from past studies have shown that Amodiaquine 
monotherapy selects P. falciparum multidrug resistance 1 (Pfmdr1) gene SNP N86Y (amino acid that 
is selected is in bold) (Sisowath et al. 2005). Resistance to mefloquine, artemisinin and Lumefantrine, 
have been associated with an increase in the copy number of the Pfmdr1 gene from experimental 
studies (Sidhu et al. 2006). Point mutations at codons 72 to 76 of the Pfcrt gene are known to cause 
resistance to chloroquine, other quinoline partner drug, and amodiaquine. However, the most prevalent 
which was associated with the world wide spread of chloroquine resistance is K76T (Djimdé 2001). 
Sulphadoxine-pyrimethamine resistance is caused by SNPs in the genes that encode dihydrofolate 
reductase and dihydropteroate synthase enzymes which are the main targets of pyrimethamine and 
Sulphadoxine drugs (Hayton and Su 2008). 
Emergence of drug resistant P. falciparum parasites in South East Asia and other parts of the world 
threatens to compromise malaria eradication and elimination efforts using all artemisinin- based 
combination therapies (ACTs) (Amaratunga et al. 2012). P. falciparum resistance to ACT is defined 
by an increase in parasite clearance rate (CR), a significant clinical indicator of drug resistance 
phenotypes, which is due to increased parasite clearance half-life (Ariey et al. 2014). In malaria 
endemic regions, artemisinin drugs are currently used in combination with other chemical 
compounds having unrelated chemical properties (Rodrigues et al. 2010). The aim is to reduce 
adaptive evolution to ACT drugs, and increase the chance of their therapeutic efficacy by making 
use of synergistic actions of their components (Rodrigues et al. 2010). The development of an 
adaptive evolution to the components of ACT in P. falciparum treatment is being studied both in 
Sub-Saharan Africa and around the globe but the discovery of the universal molecular marker for 
ACT resistance is yet to be made (Eckstein-Ludwig et al. 2003). Adaptive evolution to ACT drugs 
is still debatable but Eckstein-Ludwig et al., 2003, proposed that artemisinin exerts its anti- malarial 
activity by inhibiting the SERCA calcium ion pump and ATPase enzyme in the P. falciparum 
parasite. However, Paloque et al (Paloque et al. 2016) also observed that mutation in Pfk13 gene 
increases the quiescence capacity of P. falciparum which wades away when the ACT drug 
concentration falls below the optimal level in the 
blood. SNPs in ATPase have also been associated with the increased Inhibitory Concentrations 50% 
(IC50) of artemether in South American P. falciparum parasites (Rodrigues et al. 2010), but 
experimental evidence of ATPase involvement in ART metabolism is yet to be presented (Eckstein- 
Ludwig et al. 2003). Noedl H, et al (2009) found that Western Cambodian parasites did not have 
point mutation in the ATPase gene of P. falciparum. The parasite was confirmed to have reduced 
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susceptibility to artemisinin drugs, specifically to Artesunate (Noedl, Socheat, and Satimai 2009; 
Rodrigues et al. 2010). 
To better understand the role of SNPs in the PF3D7_1343700 gene, Ariey et al (2014) managed to 
model the K13-propeller 6-blade domain consisting of Kelch motifs made up of four anti-parallel 
beta sheets. Four SNPs including C580Y, R539T, Y493H and I543T (Ariey et al. 2014) were 
associated with an increased parasite clearance time (slope half-life). However, Ariey and colleagues 
(2014) did not measure the effects of SNPs and the evolutionary pressure due to ACT usage on the 
Kelch 13 protein by calculating the Gibbs free energy score between the wildtype and mutant Kelch 
13 protein structure. Using more advanced bioinformatics tools, the calculation of Gibbs free energy 
score enables an understanding of whether these SNPs cause a destabilization or a stabilization of 
the Kelch 13 protein and its evolutionary effects on protein stability (Pires and Ascher 2016). 
Consequently, a number of research and clinical trials have relied mostly on the parasite clearance 
rate (CR) to detect the potential drug resistant strains of P. falciparum (Hastings, Kay, and Hodel 
2015). However, this strategy does not reveal the genetic changes in the P. falciparum which arise 
long before the drug resistance becomes clinically evident. 
Hastings et al (2015), suggested that human immunity provides differences with which humans are 
differentially responsive to treatment. Therefore, parasite clearance rate (CR) is not an effective 
means for surveillance of drug resistance as it may lead to the wrong interpretations (Hastings, Kay, 
and Hodel 2015). The confounding factors which may lead to inaccurate interpretation of the results 
in clinical trials may be different pharmacokinetic activities in human, use of faulty machines for 
measurements and many more. Use of improved bioinformatics tools in the analysis of the P. 
falciparum genome has provided a prime opportunity and enabled us to deeply understand the 
within-host evolutionary dynamics of P. falciparum (Auburn and Barry 2016). To assess the effects 
of drug resistance, examination of the methodologies used in the study of drug resistance is very 
important. A SNP barcode, which is made up of 20 to 50 SNPs gives more accurate and reliable 
results compared to classical microsatellite analysis method. Daniel an d  h i s  a s s o c i a t e s  
(Daniels et al. 2008) h av e  developed a panel of 24 SNP barcode that is used globally to detect 
P. falciparum infections (Daniels et al. 2008) (Auburn and Barry 2016). These barcodes have been 
used successfully in Africa, for example in Malawi, Zambia and Senegal, in South East Asia, 
specifically Cambodia to measure complexity of Infections (CIO) and in the measurement of 
haplotype diversity (Auburn and Barry 2016). These SNP barcodes were first used in Ethiopia to 
genotype P. falciparum parasite strains collected from two different locations to measure temporal 
changes in P. falciparum transmission pattern (Daniels et al. 2008). Baniecki and his associates 
developed a 42 Single Nucleotide Polymorphism barcode for detection and mapping the geographic 
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origin of P. vivax parasite strains (Baniecki et al. 2015). These barcodes provide a universal platform 
which can be used in inferring parasite transmission patterns internationally (Baniecki et al. 2015), 
but they cannot offer an insight into the potential development of adaptive evolution in Plasmodium 
parasites during treatment using different ACT regimens. Alexander et al (2013) investigated drug 
resistance SNPs in P.  falciparum using fragment length polymorphism (RFLP) analysis and real 
time PCR (Heuchert et al. 2015), but this method cannot provide full variant information since 
adaptive evolution is a stochastic event. Mathematical modelling has been used to study the 
transmission intensity and the development of drug resistance but this doesn’t account for the within 
host evolution of malaria (Schoepflin et al. 2008). 
In Kenya, malaria parasite transmission pattern is affected by rainfall, altitude, vector species and 
the intensity of mosquito biting (Kenya National Bureau of Statistics (KNBS); ORC Macro 2010). 
Eco-epidemiologically, Kenya is divided into four main zones depending on malaria stability, with 
the Lake Victoria basins and coastal regions of Kenya having stable malaria distributions with 
approximated an annual inoculation rate of between 30 to100, epidemic highland areas of western 
Kenya, seasonal areas of North-Eastern and regions with no to very low transmission risks of malaria 
(Bejon et al. 2010). Approximately US$ 100 million is spent annually in Kenya in the fight against 
the malaria pandemic and this burden is expected to rise if the proper management and control 
measures are not put in place (Sicuri et al. 2013). The use of substandard drugs which do not satisfy 
the WHO quality standards are on the rise in the Kenyan markets and this poses a danger of 
resistance development in parasite populations as they will promote the parasite evolution to ACT 
drugs (Nayyar et al. 2012; Watsierah et al. 2011). The low bioavailability of these drugs in the 
human blood during treatment course is the main driver of within host evolution of parasites 
enabling the parasites to “acquire” new phenotype status thus becoming non-responsive to 
antimalarial treatments as reported in South-East Asia and Sub-Saharan Africa (reviewed Nayyar et 
al. 2012). This is a wakeup call for the manufactures and the policy makers who should ensure only 





Figure 1. World malaria map, tropical regions of the world still bare the greatest malaria burden. According to 
WHO 2017 malaria report, over 95% of malaria cases from Africa are caused by Plasmodium falciparum 
infections. 
1.2.3 Malaria parasite life cycle 
Malaria parasites are transmitted by female anopheline mosquitoes during a blood feed by 
depositing motile sporozoites under the skin dermis (White et al. 2014). There are more than 400 
species of anopheles and almost 20 species are of public health importance with P. falciparum 
parasite being the most lethal red blood cell infecting parasite carried by the vectors (White et al. 
2014). P. falciparum has a complicated life cycle which involves the human host and the mosquito 
as a vector (Figure 2). The asexual phase is known to take place in human and the sexual 
reproduction occurs in female anopheline mosquitoes (Hayton and Su 2008). When the mosquito 
bites a human, sporozoites in the saliva are injected with the bite, and the parasites reach the liver 
cells through blood. The sporozoite invades the hepatocytes where they multiply (Hsiao-Han 
Chang and Hartl 2014). The parasite reproduces asexually in the liver hepatocytes forming 
schizonts which then burst the hepatocytes releasing into the blood hundred thousand of 
merozoites which infect the peripheral red blood cells and start another asexual cycle (Figure 2). 
Several asexual reproduction events occur, which results in multiple invasion of red blood cells, 
with the development from trophozoite to schizont stages every two days, causing an increase in 
parasite load in the blood (Hayton et al 2008). The parasites then switch to a gametocyte stage 
(Hawking et al 19), a female anopheline mosquito takes up the gametocytes during a blood meal. 
Following a passage through the salivary gland, fertilization occurs between male and female 
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gametes. This takes place in the mosquito’s intestine resulting into the formation of ookinetes and 
then oocysts in the mosquito gut. The oocysts rupture and release sporozoites, which then move 
to the salivary glands to await inoculation at the next blood meal (H.-H. Chang et al. 2013; White 




Figure 2. Malaria parasite life cycle, involving vector and human host. 
Malaria parasite infected female anopheles’ mosquito bites human being, releasing sporozoites cells into the human’s 
dermis then into the bloodstream. Sporozoites travel through the bloodstream into the liver. In the hepatocyte cells, 
sporozoites undergoes asexual reproduction, forming merozoite cells. Merozoites then move into the peripheral 
bloodstream and infect the erythrocytes. In the erythrocytes, merozoites multiply producing thousands of merozoites, 
which then cause the erythrocytes to burst. Newly formed merozoites infect other erythrocytes.  Certain merozoites develop 
into gametocytes (male and female). When another mosquito bites the infected human being, it is ingesting the female and 
male cells (gametocytes). The mosquitos gut is where the maturation of the male and female cells occurs. The sexual 
reproduction occurs between the male and female gamete resulting in the formation of a zygote. The sporozoites are then 
formed from the zygotes through multiplication of the zygotes, the sporozoites formed then move to the mosquito’s salivary 




1.2.4 Malaria Clinical Presentation 
Malaria clinical presentation can either be severe or uncomplicated, and it remains a major risk factor 
for children under sixty months of age and pregnant women (White 2004). There is no specific clinical 
manifestation of malaria infection since it can manifest in many forms: fever, headache, muscle ache, 
fatigue, gastrointestinal disturbance, joint pain, profuse sweating mostly at night, vomiting, nausea, 
chills and diarrhea, which may occur singly or in combination (Tahita et al. 2013). When a malaria 
parasite infects an individual, the fever lasts for 12 hours and this results in exhaustion and dehydration 
of the patient (Collins and Jeffery 2005). Several malaria infections can result in severe anemia, which 
is due to a decrease in the number of red blood cells in the body (Imbert et al. 1997). Malaria clinical 
presentations vary depending on the infecting Plasmodium species. An infection by P. falciparum, 
P. ovale and P.vivax results in fever every day to 48 hours following disease onset due to schizont rupture 
and destruction of red blood cells (Collins and Jeffery 2005). Of all the Plasmodium species, P. 
falciparum is known to cause the most severe malaria and highest mortality rate. It causes convulsions, 
severe headache and high fever (Lalloo et al. 2007). P. falciparum cause severe malaria resulting in 
cerebral malaria, acute renal failure and pulmonary edema (Trampuz et al. 2003). After treatment of 
infections resulting from P. vivax and P. ovale, some schizonts which “hide” in the hepatocytes, 
become dormant for a period ranging from 90 days to five years (Lalloo et al. 2007). These schizonts 
may later enter the blood stream periodically causing malaria relapse (Collins and Jeffery 2005). The 
prolonged stay of schizonts in the host liver may results in a new variant of Plasmodium with different 
phenotypes from the initial infecting parasite due to evolution in the host (Gardner et al. 2011).  
1.2.5 Malaria diagnosis 
Fast and accurate detection of malaria parasites is essential for the treatment of infected individuals 
and it also helps in controlling further transmission of malaria in a population (Oriero et al. 2015). 
The microscopy test remains the main diagnostic tool in most resource-limited settings (Musuva et 
al. 2017). In addition to microscopy, rapid diagnostic test (RDT), isothermal amplification, serology, 
fluorescent microscopy and Polymerase Chain Reaction (PCR) can also be used for the detection of 
malaria parasite in the blood (Britton, Cheng, and McCarthy 2016; Torrus et al. 2015). Before 
administration of antimalarial therapy in most health facilities, malaria parasite detection is done 
using microscopy by examining the peripheral parasites in a thick or a thin (used in identifying the 
species of infecting Plasmodium) blood smear or rapid diagnostic test (RDT) which detects the malaria 
parasite antigen (Histidine rich protein 2, HRP2) in the blood as recommended by the World Health 
Organization (WHO 2010; Guy 1992). PLDH-based tests has an 85% sensitivity while HRP2 has 
92%, and according to a study which was conducted in Kampala, Uganda in children by Hopkin et 
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la (Hopkins et al. 2007) the pLDH-based tests had 100% in malaria detection and HRP2 had 93%. 
All these tests can still be used for the detection of P. falciparum infection before any ACT drug is 
prescribed (Hopkins et al. 2007). Accurate microscopy tests can also be used to quantify malaria 
parasites (thick smear) as well as to detect different species (thin smear) of malaria parasites (Payne 
1988;). The molecular diagnosis of malaria parasite is the most accurate diagnostic test to date due to 
the high sensitivity of PCR with the lower limit of detection of 0.22 parasites per microliter (Britton, 
Cheng, and McCarthy 2016). It also provides an accurate determination of the Plasmodium species 
within a population of parasites (Thongdee et al. 2014). 
The loop-mediated isothermal amplification test is a fast and simple nucleic acid amplification tool 
for malaria diagnosis (Mori et al. 2001). The detection of parasite’s nucleic acid is made easy by 
interpreting the turbidity test. A higher turbidity shows the presence of high parasitemia while a low 
turbidity indicates the presence of low parasitemia (Mori et al. 2001; Britton, Cheng, and McCarthy 
2016). Loop-mediated isothermal amplification has been used in malaria surveillance in research 
centers and major malaria reference laboratories to provide a molecular diagnostic tool in the fight 
against malaria in different regions of the world (Sattabongkot et al. 2014). Immunochromatographic 
tests include RDT, which detects the presence of histidine-rich protein 2, which is specific to P. 
falciparum. Some RDTs detect parasite lactase dehydrogenase (pLDH) or aldolase, which can also 
be used to distinguish P. falciparum infections from non-P. falciparum infections, for example 
Plasmodium vivax (WHO 2010). 
1.2.6 Malaria Treatment 
With accurate and timely diagnosis, malaria is treatable with antimalarial such as Artemisinin 
Combination Therapy (ACT) and quinoline drugs (Boyce et al. 2015; Kazembe, Appleton, and 
Kleinschmidt 2007). The World Health Organization (WHO, 2015), recommends four main factors 
to be considered before the administration of antimalarial drugs to malaria patients. It includes 
whether the patient is suffering from complicated or uncomplicated malaria, the type of infecting 
species of malaria parasite, high risk groups such as infants and pregnant women, and treatment 
response, depending on drug resistance patterns in a given geographic location (World Health 
Organization 2015a). P. falciparum resistance to almost all the available antimalarial drugs prompted 
the World Health Organization to endorse dual or triple dosage of antimalarial drugs to be used in 
malaria treatment. These antimalarial drugs which are made up of molecules with distinctive mode 
of action or different target enzymes (Paloque et al. 2016). Combination therapy is much more 
effective and should the parasite develop resistance to one component of the drug the partner drug 
molecule will clear the resistant P. falciparum parasites. The commonly used ACT drugs are: 
Artemether- Lumefantrine, Artesunate-Amodiaquine, Artesunate-Mefloquine, Dihydroartemisinin-
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piperaquine and Sulphadoxine-Pyrimethamine administered over a period of 72 hours (World Health 
Organization 2015a). 
For more than four decades, Chloroquine has been used in the treatment of uncomplicated infections 
of P. vivax, P. ovale, P. malariae, and P. falciparum (Visser et al. 2014). Sulphadoxine- 
pyrimethamine (SP), doxycline, mefloquine, atovaquone, proguanil hydrochloride combination, 
quinine, and primaquine were also used in the treatment of malaria (Hayton and Su 2008; Lalloo et 
al. 2007). However, Sulphadoxine-pyrimethamine, chloroquine and amodiaquine must not be 
prescribed to patients who are infected by P. falciparum after diagnosis because of the high- level of 
resistance to these drugs which has developed because of their usage as monotherapy drugs (Paloque 
et al. 2016). In 2015, the World Health Organization adopted the use of ACTs, for the treatment of 
uncomplicated malaria caused by P. falciparum in malaria endemic locations of the world (World 
Health Organization 2015b). Quinine was recommended for treatment of uncomplicated P. 
falciparum infection in pregnant women in their first trimester as well as in infants, while Artesunate 
and artemether use were recommended in the second and third trimester. The WHO strongly 
recommends the use of Sulphadoxine/Pyrimethamine for Intermittent preventive treatment (IPT) in 
pregnant women in Sub-Saharan Africa and other malaria endemic regions of the world, where a 
large number of deaths are registered due to malaria in pregnancy (Vinayak et al. 2010). 
Sulphadoxine is an antifolate which inhibits the enzymatic functions of the dhps enzyme used in the 
folate biosynthesis in P. falciparum parasite. Patient behavior, such as non-adherence to antimalaria 
treatment, provides a prime advantage for to undergo adaptive evolution resulting in new species of 
parasites with a different genetic make-up which become later non-responsive to antimalarial 
treatment (Vinayak et al. 2010). 
1.2.7 Malaria Vaccine 
Despite efforts to develop malaria vaccines for the past 70 years (CLYDE et al. 1973), no effective 
malaria vaccine is available on the market (Hoffman et al. 2015). An effective vaccine is needed to 
reduce disease burden (Keitany, Vignali, and Wang 2014). The complex P.  falciparum life cycle 
(see Figure 2) within the mosquito gut and the human host is a great challenge in malaria vaccine 
development (Draper et al. 2015). The differential antigen expression after the inoculation of the 
sporozoites in the skin dermis, in the hepatocytes before migration to the peripheral blood stage, and 
the capability of undergoing antigenic variation complicates vaccine development process (Keitany, 
Vignali, and Wang 2014). Several vaccines have been developed against malaria. The vaccines were 
based on PfCelTOS, PfMSP1, PfAMA1, PfRH5, PfSERA5, PfGLURP, PfMSP3, Pfs48/45 and Pfs25 
(Draper et al. 2015). Despite all these attempts there is no licensed malaria vaccine to date. This can 
be explained in part to the complex malaria parasite’s life which involves the human host and mosquito 
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vector, and the ability of P. falciparum to curb and evade the human host immune system, which 
poses major challenges (Lusingu and Von Seidlein 2008). RTSS has been shown to be effective and 
is currently undergoing clinical trials in Sub-Saharan Africa specifically in East Africa (Tanzania and 
Kenya) and Central Africa, where it has been shown to be safe and immunogenic in children below 
the age of 5 years, but the vaccine protection reduces after six months following its administration 
(Sacarlal et al. 2008; Lusingu and Von Seidlein 2008; Campo et al. 2014). Despite the continued 
efforts and research to discover an effective vaccine, more challenges than gains are still at play. 
Differential expression of var, and msp1, msp2 surface protein genes during the life cycle of P.  
falciparum complicates the efforts in discovery of the right vaccine (Lusingu and Von Seidlein 2008; 
Frank Hawking, Wilson, and Gammage 1971). Complex morphological development of P.  
falciparum from stage I-V (See Figure 2) enables the parasite to survive within the host and evade 
drugs.  
1.2.8 Immunity 
After several malaria infections, people living in high malaria transmission settings develop partial 
immunity against malaria (Arama et al. 2014). This partial immunity does not protect an individual 
from subsequent malaria infections, but it protects them against severe effects of malaria infections 
(Schwenk et al. 2011; Arama et al. 2014). High malaria mortality rate and severe illness in malaria 
transmission regions of the world occur in young children below the age of five, pregnant women 
and infants (Roca-Feltrer, et al. 2008). Infants and children get easily infected with malaria because 
their immune system has not matured to provide effective protection against the infecting malaria 
parasite. Immune suppression during pregnancy in women, make them highly susceptible to malaria 
infection (Roggelin et al. 2014). In the placenta, malaria parasites attach to the blood capillary, which 
results in the perturbation of blood circulation in the placenta resulting in reduced supply of nutrients 
to the fetus (Fitri et al. 2015). P.  falciparum infection in pregnant women is the leading cause of 
stillbirth and miscarriages reducing the survival rate of infants born in malaria endemic areas 
(Roggelin et al. 2014). The P.  falciparum gametocyte must evade the human host immune clearance 
during development for it to mature. This is thought to be due to sequestration of bone marrow for a 
better part of their development period, and it is after that when they are released to circulation upon 
maturation (Delves et al. 2016). The gametocytes also become insensitive to the antimalarial regimen 
which is used to treat malaria (Delves et al. 2016). Insensitivity problems posed by mature 
gametocytes to antimalaria drugs results in a situation where an individual is cured of malaria but 
still harbors gametocytes. This promotes the disease circulation in the population if proper monitoring 




Kisumu County is located along the shores of Lake Victoria and is a stable malaria transmission 
setting with several malaria hotspots including the Kombewa and Maseno divisions (Bejon et al. 
2014; Sifuna et al. 2014). Until recently, the analysis of P.  falciparum genomic sequence data has 
not provided a unifying explanation for the parasite evolution following the introduction of 
Artemisinin Combination Therapy treatment in Kenya even though some SNPs have shown 
significant association with elevated IC50 values (Ngalah et al. 2015). More insight can be obtained 
by understanding the impact of ACT pressure on the P.  falciparum genome and their evolutionary 
effect. A better understanding of the evolutionary dynamics occurring during treatment in P.  
falciparum is needed to help control the disease. In this thesis, we aim to understand the evolutionary 
changes occurring within-host due to ACT usage and how this could affect the treatment outcome in 
Kenya. The findings will enable us to identify the priority areas of further research to fully understand 
the evolutionary causes of drug resistance and management of malaria in the population. 
 
1.3.0 Study Aim 
To determine the within-host evolution of the P.  falciparum parasite during treatment with ACTs 
and investigate the presence of drug resistance signatures. Main objective 
1.3.1 Main objective 
To investigate the evolutionary changes in the P.  falciparum genome due to Artemisinin 
Combination Therapy intervention in Kenya between 2013 and 2015. 
Specific objectives 
1. To determine the presence of selection signatures in the P.  falciparum genome due to 
ACT usage between 2013 and 2015. 
2. To determine the association between Single Nucleotide Polymorphisms and IC50s of ACT 
drugs, clearance half-life and clearance rate. 
3. To investigate the effect of single nucleotide polymorphisms on the Kelch 13 propeller 
domain. 







Chapter 2. Materials and Methods 
2.1 Study site 
Overview 
The sample collection was conducted within the Kombewa and Maseno Divisions of the Kisumu West 
District of Kisumu County in Kenya. Study activities were coordinated from the Kombewa Clinical 
Research Center located in Kombam village, Kombewa (Figure 3). The study site is located about 40 
km west of Kisumu city, the administrative capital of Kisumu County. The study divisions cover an 
area of about 369 km2 stretching on the North-Eastern shores of Lake Victoria where malaria is 
holoendemic (Watsierah et al. 2011). The study area has been cartographically mapped by the KEMRI- 
WRP Kisumu West Health and Demographic Surveillance System (KWHDSS) using Global 
Positioning System (GPS) technology. “The KWHDSS is a longitudinal population registration 
system designed to track the evolving demographic and health status of the study populations over 
time. The KWHDSS population is monitored by field staff visiting each household bi-annually to 
capture health and demographic information. Various studies nested on this platform take advantage 
of the sampling frame inherent in the Health Demographics Surveillance System (HDSS), whether 
at individual, household/compound or regional levels” (Sifuna et al. 2014). Kombewa (34°45’ E 0°10 
S) lies within the Lake Victoria basin (Sifuna et al. 2014) (see Figure 3). Malaria in Kombewa is 
holo- endemic, with P.  falciparum accounting for more than 95% of single-species infections. Little 
information is available regarding mixed infections and Malaria transmission occurs throughout the 
year. The ‘long rainy season’ from late March to May produces intense transmission from April to 
August. The ‘short rainy season’ from October to December produces another less intense 
transmission season from November to January” (Bejon et al. 2010). Anopheles gambiae and 
Anopheles funestus are the major vector species with a noted increasing population of Anopheles 
arabiensis in recent years. There is limited published malariometric data from Maseno (34°36’ E, 
0°0’ S). For these two study sites we set out to understand the evolutionary forces conferring drug 
resistance development in the most lethal P. falciparum. 
2.1.0 Study design 
This was a two-arm randomized open-label trial study which was conducted at the Kombewa 
clinical Research Centre. Patients presenting with uncomplicated malaria at health facilities within 
the study area was referred to the research center and enrolled into the study after signing an informed 
consent form. Those who had parasite density ranging from 2000 to 200000 parasites/µl, willing to 
comply to the study protocol for the study period, and had a mono-infection of P.  falciparum was 
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included in the study. Requirements were adults and children aged between six months and sixty-five 
years with the minimum weight of 11 kg and having fever with a body temperature greater or equal 
to 37.50C or an history of fever within 24 hours prior to presentation to the facility. Detailed 
information on genotyping of SNPs using Sequinome Mass Array technology has been published 
by Ngala et al and is available online (Ngalah et al. 2015). Fifty-nine (59) samples from 2013 and 
sixty-eight (68) from 2015 were analyzed. Those satisfying the above conditions and were willing 
to remain in the facility for a period of 72 hours were also included in the study. Subjects showing 
signs of severe malaria who were unable to take oral medication were excluded from the study. 
Ethical approval for this study was obtained from Kenya Medical Research Institute Ethics review 
committee (SSC #2722), and the University of Cape Town, Human Research Ethics Committee 
(HREC REF:539/2017) gave approval for data analysis. In addition to the above-mentioned IRBs, 












2.1.1 Assessing the presence of selection signatures between 2013 and 2015 
To identify whether Artemisinin Combination Therapy (ACT) intervention causes selection in P.  
falciparum parasites from Kenya, Tajima’s D, Fu & Li’s F*, and Fu & Li’s D* summary statistics 
were calculated using the DNA sequence polymorphism analysis software, DnaSP V6 (Librado and 
Rozas 2009). The analysis was conducted to evaluate whether the P.  falciparum Kelch 13 propeller 
domain molecular sequence displays evidence of departure from the neutral model of molecular 
evolution (Tajima 1989). A total of forty-six sequences from the 2013 sequence data set and seventy-
two sequences from the 2015 data set were analyzed. Multiple Sequence Alignment (MSA) was done 
using the MUSCLE alignment program (Edgar 2004) implemented in the Aliview software (Larsson 
2014), which was also used to visualize the alignment of the sequences using the SeaView V4 (Gouy, 
et al. 2010) visualization program. Aligned sequence data were then exported into DnaSP V6 
(Librado et al 2009) for calculations of Tajima’s D, Fu and Li D*, and Fu & Li’s F* (Fu and Li 1993). 
In DnaSP the simulation is used to estimate the Tajima’s D (Tajima 1989), Fu and Li’s D* (Fu and Li 
1993), Fu and Li’s F* (Fu and Li 1993) genomic summary statistics. Information on the allelic 
variation in the sequence data is used in the test (Ramírez-Soriano et al. 2008). These three test 
statistics are based on the assumption that under the neutral model, there is a correlation between the 
estimated number of polymorphic sites and the average nucleotide diversity (Tajima 1989). In the 
calculation of Tajima’s D (Tajima 1989), average nucleotide diversity between two sequences (π) and 
the total population nucleotide diversity are taken into account (Tajima 1989). Haplotype diversity 
which is the analogue of the allele frequency-based calculation was also conducted. Fu and Li’s D* 
(without an outgroup) tests the difference between total number of singletons and the total number 
of mutations occurring within the sequence (Fu and Li 1993). Fu and Li’s F* (without an outgroup) 
summary statistic is based on the difference between the number of singletons and the average 
nucleotide difference between sequence pairs (Fu and Li 1993). The genomic summary statistics 
values obtained from this analysis were used to interpret the results under the neutral model of 
evolution (Fu and Li 1993; Tajima 1989; Ramírez-Soriano et al. 2008). To infer the directionality and 
magnitude of adaptive evolution acting on the Pfk13 protein coding gene (PF3D7_1343700) due to 
ACT intervention, the synonymous mutation per synonymous site and non- synonymous mutation 
per non-synonymous mutation ratio were calculated. Nucleotide sequences from 2013 and 2015 
sample data were first converted into amino acid sequences by EMBOSS TranSeq located at 
(www.ebi.ac.uk). The amino acid sequences were then aligned using the MUSCLE alignment 
program (Edgar 2004) implemented in Aliview (Larsson 2014). The aligned sequence data was 
transferred to Synonymous Non-Synonymous Analysis program (SNAP v2.1.1) webserver    for 
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dN/dS calculation and visualization analysis. The analysis involved forty-six amino acid sequences 
from the 2013 dataset and seventy-two amino acid sequences from the 2015 data set. The 1st, 2nd and 
3rd codon positions were included in the analysis. All the ambiguous positions were removed from 
each sequence pair. The summary statistics values obtained from these analyses were used to predict 
the adaptive evolution due to ACT intervention within the P.  falciparum genome. 
2.1.2 Determining the effect of mutations on Kelch 13 propeller domain 
2.1.2.0 Using the graph-based signature method 
Mutation is the primary driver in evolution as it plays a role in the introduction of diversity in a 
population of P.  falciparum parasites (Pires et al. 2014). The non- synonymous mutations in the 
coding regions of Kelch 13 genes may provide a selective advantage or disadvantage to the P.  
falciparum parasite by affecting Kelch 13 protein stability. To understand the effects of mutations on 
P.  falciparum Kelch 13 propeller domains and the development of adaptive evolution against the 
Artemisinin Combination Therapy drugs, the effects of point mutations (Single Nucleotide 
Polymorphisms) on the Kelch 13 protein were assessed. The wildtype Kelch13 protein data file 
(PDB_ID_4yy8) was downloaded from the 3D protein database website (www.rcsb.org). The effect 
of single nucleotide polymorphisms (SNPs) on the Kelch 13 protein structure was determined using 
the mCSM (Pires, Ascher, and Blundell 2014) webserver (http://biosig.unimelb.edu.au/mcsm/). The 
input file (text file) containing the chain name in the first column and the second column having non-
synonymous amino acid substitutions information at different loci within the Kelch 13 domain was 
created from the SNP array data. The wild-type protein data bank (pdb) file together with the mutation 
list was submitted for the analysis. 
2.1.2.1 Using SDM to infer the effects of mutations on Kelch 13 protein structure 
To further validate the mCSM results, an environment specific substitution table (ESST) (Pandurangan 
et al. 2017) was used to calculate the energy difference between the wildtype Kelch 13 protein and the 
mutant protein structure. The Site Directed Mutagenesis (SDM) web server (http://131.111.43.103/) 
was used in the calculation of the thermodynamic energy difference between wildtype and mutant 
Kelch 13 propeller domain (Pandurangan et al. 2017). The text file containing the list of point 
mutations at different codons was created as described in the mCSM procedure above. The Kelch 13 
protein data file in Protein Data Bank (PDB) format was downloaded from the protein databank 
(PDB_ID 4yy8). This, together with the text file containing the mutation list were submitted to the 




2.1.2.2 Location of point mutations on Kelch 13 protein 
Determination of non-synonymous point mutation locations on the Kelch 13 protein structure is 
fundamental as it enables the visualization of the loci under evolution due to drug pressure. Using the 
PRotein Interactive Modelling (PRIMO) online homology modelling tool (Hatherley et al. 2016) 
(https://primo.rubi.ru.ac.za), the wildtype structure of P.  falciparum Kelch 13 protein structure was 
determined. The Kelch 13 sequence comprising of 726 amino acids was downloaded from the 
UniProt database (Protein ID: Q8IDQ2). The PF3D7_1343700 was used as a target protein sequence 
and using the Basic Local Alignment Search Tools (BLAST) algorithm the best protein template was 
identified from the Protein Databank. The PDB ID 4yy8 with 100% identity, 53% coverage and a 
resolution of 1.81 Å (Angstrom) was identified. The target-template alignment was done using the 
MUSCLE (Edgar 2004) alignment program within PRIMO. The modelling of the target sequence was 
done using the slow refinement modelling algorithm. 
2.1.2.3 Artemisinin Combination Therapy drugs and Kelch 13 protein interaction 
The mutations associated with the high Inhibitory concentration 50% are found on chain A as shown 
in figure 6. Since the Kelch 13 propeller protein is made up of two main chains, we investigated the 
ACT drug interaction sites with the Kelch 13 protein domain. The drug/ligand was extracted from the 
wildtype Kelch 13 protein, which was downloaded from the UniProt database in PDB format. Babel 
was used to convert the wildtype drug/ligand file to .sdf format. Using the Posview web server 
(https://proteinplus.zbh.uni-hamburg.de/), the wildtype protein file and the ligand .sdf files were 
uploaded for the analysis. 
2.1.3 IC50, Slope-half life and SNP association analysis in 2015 
Point mutations (SNPs) have been associated with both Artemisinin and quinoline derivatives 
treatment failure and increased parasite clearance rate from Sub-Saharan Africa and in South East Asia 
(Picot et al. 2009; Foote et al. 1990; Djimdé 2001; Amaratunga et al. 2012; Eckstein-Ludwig et al. 
2003; Ariey et al. 2014). The association between SNPs and the half maximal inhibitory concentration 
50% of P.  falciparum isolates were done to determine the relationship between IC50s and SNPs at 
different loci using SNParray and IC50 data. The main goal was to determine if there was an 
association between these genetic variants and the increased IC50 values of different ACT drugs. The 
following drugs were used for the analysis: amodiaquine, mefloquine, dihydroartemisinin-
piperaquine, artemether and lumefantrine. A custom python script was used to clean the data by 
removing missing data points. The categorical predictors (SNPs) were then converted to binary 
numbers with zero (0) denoting wild-type variant and one (1) denoting mutant variant using another 
custom python script. After cleaning the data, R version 3.4.2, was then used in the downstream 
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analysis of the data. A general linear regression model in R v3.4.2 (R Development Core Team 2016) 
was used to predict the association between SNPs, slope half-life and IC50 values. A Pearson 
correlation test was done to determine the correlation between different antimalarial drug IC50 values 
as it may provide an insight into the similarity in their therapeutic activities. Sometimes, therapeutic 
agents with negative correlation values can reveal synergistic partner drugs for rotational deployment 
in population. A cut-off alpha value of ≤ 0.05, was considered to be statistically significant. The 
student t-test was used to determine if there was a significant difference in parasite clearance rate 
between Artemether lumefantrine and Artesunate amodiaquine treatment arms respectively. 
2.1.4 Determination of within-host population differentiation as a measure of 
evolution 
P.  falciparum parasites at different time points were considered as distinct parasite populations. 
The hour zero day zero (H0D0) parasites were considered as the first population (population 1), day 
one hour twenty-four (D1H24) as population 2, day two hour thirty (D2H30) as population 3, day 
one hour thirty-six (D2H36) as population 4, day one hour forty-two (D2H42) as population 5, day 
two hour forty-eight (D2H48) as population 6, day twenty-eight as population 7, day thirty-five as 
population 8 and day forty-two as population 9. Microsatellite data was managed in an Excel spread 
sheet, from which the data was formatted to form the input for other microsatellite analysis 
programs. A custom python script was used to remove the missing data points. The value 2 was 
entered in cell A1 since our data was a two-column format. Parasite population names were entered 
in the first column, ensuring that no cell remained empty. Since the Plasmodium genome is haploid 
within the human host, the alleles were entered twice to mimic the diploid state of the organism. 
The input data format was prepared in Excel and then saved in tab delimited format. Using the 
Microsatellite Analyzer V 4.05 (Chu 2003), P.  falciparum population differentiation at different 
time points was estimated by calculating the Wright FST values. During the analysis, the input file was 
saved in the same directory where the MSAanalyzerMr.exe executable was, which was then used to 
specify the input parameters and run the analysis. The Microsatellite Analyzer was also used to 
generate other data file formats (“data wrangling”) such as gene pop, structure and Arlequin input 
data files. Genepop, the output data format from Microsatellite Analyzer was transferred to R v3.4.2 
(R Development Core Team 2016) for the downstream analysis. Various population genetic analysis 
packages were installed in R v 3.4.2 (R Development Core Team 2016) which include: poppr 
(Kamvar, et al. 2015), diveRsity (Keenan et al. 2013), adegenet (Jombart 2008), vegan (Oksanen et 
al. 2016) ggplot2 (Wickham 2009) and Discriminant Analysis Principle Components (DAPC) 
(Jombart et al. 2010). This was used to visualize genetic hierarchical clustering of P.  falciparum 
during treatment, allele richness and FST.  FST (Nei and Genetics 1973) was used to measure the 
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genetic variability within and between P.  falciparum populations during treatment because it 
considers differences in multi allele frequencies. For interpretation of FST < 0.05, was defined as low 
or no genetic differentiation, ≥0.05 FST < 0.15, moderate differentiation and finally FST ≥ 0.15 
denoting large genetic differentiation (Gatei et al. 2010). 
2.1.5 Phylogenetic tree construction 
Multiple sequence alignment (MSA) was done using MUSCLE (Edgar 2004) in Aliview (Larsson 
2014). The Aligned sequence data was saved in Newick format which was then transferred to the 
Recombination Detection Program (Martin et al. 2000) for phylogenetic tree construction. A 
Maximum likelihood phylogenetic tree was constructed using the General Time Reversible (GTR+ 
G4) substitution model. The iTol phylogenetic tree editor and annotation program available at 



















Chapter 3. Results 
This research sought to investigate the evolutionary changes in the P.  falciparum genome due to 
Artemisinin Combination Therapy intervention in Kenya using samples collected in Kombewa and 
Maseno divisions between 2013 and 2015. We aimed to determine the presence of selection signatures 
in the P.  falciparum genome due to ACT usage between 2013 and 2015. In addition, the study aimed 
to determine the association between Single Nucleotide Polymorphisms and half maximal inhibition 
concentration of ACT drugs, clearance half-life and clearance rate. Finally, we investigated the effect 
of SNPs on the Kelch 13 propeller domain and determined the within-host population differentiation 
as a measure of evolution. 
Wright’s F-statistic is very popular since it has been around for a long period of time (Holsinger et al 
2009). FST gives a very important insight which help in the explanation of different evolutionary 
processes that affects the genetic variations within and among populations of interest. It is the most 
widely used genomic summary statistic and in evolutionary genetics (Holsinger et al. 2009). The 
Wright’s F-statistic, has been used to identify regions of a genome which are under selection (Chen et 
al. 2004). The Fst values range from 0 to 1, with the zero values indicating no differentiation and 1 
indicates that the alleles under study are fixed (Chen et al. 2004; Keenan et al. 2013). D Jost, GST and 
G’ST are the analogues of the FST and their interpretations are the same as those of FST (Keenan et al. 
2013). Tajima’s D test is used to compare the average number of pairwise differences and the total 
number of segregating sites in a sample being analyzed (Ramírez-Soriano et al. 2008). The negative 
Tajima’s D test implies positive selection, whereas positive Tajima’s D indicates negative selection 
while Tajima’s D of 1.00 shows that the genomic sequence under study is under balancing selection 
(Ocan et al. 2016; Oyebola et al. 2017; Tajima 1989).  
3.1.0 Neutral models of evolution between 2013 and 2015 
In 2013, the P.  falciparum parasite genome was under balancing selection as shown by the significant 
positive Tajima’s D value of 4.53194 and a p-value less than 0.001 (Figure 4). Since the parasite’s 
genome was under balancing selection, the wildtype alleles remained longer in this parasite 
population since the introduction of ACT drugs in 2006. There was a lack of SNPs as shown by a 
significant positive Fu & Li D* value of 2.13380 (Figure 4), a p-value of 0.02 and a Fu &Li F* value 
of 3.62142 and a p-value of 0.02. P. falciparum parasites in 2013 showed a low level of variability 
with the haplotype diversity (Hd) parameter of 0.552 and a nucleotide diversity (π) coefficient of 
0.20892. In 2015 P. falciparum parasites showed a higher level of diversity (Hd = 0.832) with a 
nucleotide diversity (π) of 0.00302. There was a significant negative Tajima’s D (-2.42910) (Figure 
4), and p-value < 0.01, indicating that the P.  falciparum genome in 2015 was under a selective sweep. 
There were excess singletons as shown by the significant Fu and Li’s D* statistics ( -5.2712, p-value 
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<0.02) and a significant negative Fu and Li’s F* (-5.0045, p-value < 0.02). 
  
3.1.1 Synonymous and non-synonymous mutation between 2013 and 2015 
The averages of all pairwise comparisons of sequence data in 2013 were dS=0.0039 and dN=0.0050 
(see Figure 4). The dN/dS (Li 1993) ratio was 1.0299 (Figure 5), an indication that in 2013, the P. 
falciparum genome was under neutral selection as shown by the very low rate of synonymous and 
non-synonymous mutations at the protein coding loci. This evidence is supported by significant 
positive values of Tajima’s D, Fu and Li’s F* and Fu & Li’s D*. The synonymous (dS) mutation 
rate was 0.0108 and non-synonymous (dN) rate was 0.0052 in the 2015 sequence data set (Figure 4). 
The dN/dS (Li 1993) ratio was 2.84, an indication that in 2015, the P. falciparum genome was under 




Figure 4. Estimates of neutrality model of evolution between 2013 and 2015. In 2013 Tajima D, Fu and Li 
D*, Fu and Li F* were all positive, signifying balancing selection and lack of singletons respectively, while in 
2015 Tajima D, Fu and Li D*, Fu and Li F* were all negative, an indication of selective sweep and increased 





Figure 5. Synonymous and non-synonymous mutations between 2013 and 2015, the synonymous and non-
synonymous mutations in 2013 were very low, while in 2015 there was an increase in non-synonymous point 
mutations, which is consistent with the SNP array data results. Evolutionary effects of mutation on Kelch 
13 propeller domain 
3.1.2.0 Using the graph-based signature method 
The Kelch 13 propeller protein is composed of two chains (chain A and B) (Ariey et al. 2014). For 
chain A, the change in Gibbs free energy (∆∆ D) score was used to infer the effect of different SNPs 
resulting in amino acid changes (non-synonymous mutations) within the Kelch 13 propeller domain. 
The non-synonymous mutations at codons N632K and R561P gave a positive Gibbs energy score, 
indicating the stabilization effects of these mutations in the Kelch 13 protein structure (Pires et al. 
2014). Negative Gibbs free energy values indicate that the mutation causes destabilization of the 
protein, with Gibbs free energy score values > -2 showing a high destabilization effect of those SNPs 
on the protein structure (Pires et al. 2014). From the Gibbs free energy scores, (see Table 1) the non-
synonymous mutation at the D547E which occurs at highest frequency, causes minimal 









Table 1: SNPs and Gibbs free energy score (mCSM webserver results). Gibbs free energy score can either be 
negative or positive which a destabilization and stabilization effect on protein. 
PDB_FILE Wildtype Codon_pos Mutant type Gibbs score 
Kelch_WT.pdb V 568 G -2.14 
Kelch_WT.pdb T 677 A -1.029 
Kelch_WT.pdb G 639 R -1.461 
Kelch_WT.pdb I 640 V -1.564 
Kelch_WT.pdb N 632 K 0.072 
Kelch_WT.pdb L 571 S -3.566 
Kelch_WT.pdb R 561 P 0.428 
Kelch_WT.pdb D 559 E -0.862 
Kelch_WT.pdb A 557 T -1.545 
Kelch_WT.pdb Y 558 N -3.039 
Kelch_WT.pdb D 547 E -0.711 
Kelch_WT.pdb G 496 A -1.629 
Kelch_WT.pdb F 483 L -2.331 
Kelch_WT.pdb F 451 S -2.724 
Kelch_WT.pdb F 628 L -0.912 
Kelch_WT.pdb C 542 G -1.664 
Kelch_WT.pdb N 489 K -0.326 
 
As shown in Table 2, these SNPs affect the stability of the Kelch 13 propeller domain and its 
conformational arrangement in space. To further validate the effects of these SNPs on this protein, site 
directed mutagenesis which uses the conformationally constrained environment-specific substitution, 
gave the energy difference between the wildtype Kelch 13 propeller domain and the mutant Kelch 
13 protein. 
More than one hundred thousand genetic variants are associated with different disease 
conditions in human beings (Burgess et al. 2015). The main challenge is the identification and 
characterization of target genetic variants and their functional effects on the protein folding and 
biochemical activities. Of interest are non-synonymous SNPs that affect the function of the 
protein by affecting their folding in space and they also interfere with the normal protein 
interaction with other biomolecules in the cell (Pires et al. 2016; Pandurangan et al. 2017). To 
further validate the effects of our SNPs on the Kelch 13 protein (Table 1), we also used the Site 
Directed Mutagenesis SDM to predict the impact of these mutations on Kelch 13. These SNPs 
caused either destabilization or stabilization in the Kelch 13 protein. We observed the 
stochastics effects of these SNPs on WT_RSA (Wildtype Relative side chain Solvent 
Accessibility), MT_RSA (Mutant Relative side chain Solvent Accessibility), WT_OSP (Wild- 
type residue-occluded packing density), MT_OSP (mutant residue-occluded packing density). 
The ddg (∆∆ Gibbs free energy score) showed that these SNPs cause stabilization and 







Table 2: Using Site Directed Mutagenesis to predict protein stability (SDM webserver results). *WT_RSA 
(Wildtype Relative side chain Solvent Accessibility), MT_RSA (Mutant Relative side chain Solvent 
Accessibility), WT_OSP (Wild-type residue-occluded packing density), * MT_OSP (mutant residue-occluded 
packing density), ddg (∆∆ Gibbs free energy score) 
Mutation WT_RSA(%) WT_depth WT_OSP MT_RSA(%) MT_depth(A) MT_OSP Predicted 
V568G 11.5 4.9 0.4 55.8 4.1 0.26 -1.78 
T677A 43.9 3.7 0.26 37.1 3.4 0.26 -0.5 
G639R 0 7.7 0.65 0 8.2 0.8 -2.89 
I640V 11.7 4.5 0.54 6.8 4.4 0.55 -1.97 
N632K 70.4 3.2 0.24 86.7 3.3 0.15 -0.16 
L571S 0 8.1 0.55 2.2 7.3 0.43 -3.07 
R561P 51.5 3.1 0.13 78.9 3.3 0.17 -0.42 
D559E 26.5 3.9 0.44 29.6 3.9 0.41 0.35 
A557T 0 6.5 0.57 0 6.3 0.65 -1.73 
Y558N 1.6 7.1 0.52 3.7 8 0.46 -2.66 
D547E 25 4 0.43 41.6 3.9 0.35 -0.35 
G496A 0 8.7 0.53 0 9.1 0.6 -1.7 
F483L 0 7.8 0.53 0 8.2 0.46 -2.46 
F451S 19 4.1 0.54 15.7 4.6 0.49 -0.64 
F628L 2.7 6.9 0.54 2.9 6.8 0.5 -1.87 
C542G 0 10.1 0.59 0.8 10.3 0.49 -2.09 








Figure 6. Location of point mutations on the Kelch 13 protein, the red sphere is a C580Y SNP which has been 
extensively reported in SEA and is associated with reduced parasite clearance rate. The yellow and blue spheres 
show the Kenyan SNPs which are likely to be associated with treatment failure. 
 
C580Y is associated with the increased parasite clearance rate in the South East Asian (SEA) P. 
falciparum parasites (Ariey et al. 2014). D547E and D559E are associated with high risk of treatment 
failure in the Kenyan (KE) P. falciparum parasites. PF3D7_1343700 is a homologous structure to 
human Kelch-like ECH-associating protein 1 (KEAP1) (Ariey et al. 2014). Both SNPs from Kenyan 














Figure 7. Kelch 13 propeller domain showing the predicted binding pocket of ACT drugs. The red molecules 
show the drug binding pockets and the blue colors shows the propeller domain.  
 
Figure 8 ACT drugs/Kelch 13 protein interactions, drug molecules are shown in red and blue dots and they 
mostly interact with chain A (Posview drug/ligand interaction prediction tool). 
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3.1.2.3 IC50, Slope-half life and SNP association analysis in 2015 
There was no significant association between SNPs, Inhibitory Concentration 50% and parasite 
clearance slope half-life. However, there was a significant association between IC50 and codon 
D559E in Amodiaquine (AQ) and Mefloquine (MQ) IC50 (p-value 0.0189, OR=0.9664, 95% 
Confidence Interval (0.9186-0.9907), and P-value 0.0175, OR=1.044, 95% Confidence Interval 
(1.01-1.08), respectively). Codon D547E also had a significant association with the Artesunate half 
maximal concentration 50%, p-value 0.0358, OR= 1.046, 95% CI (0.001 – 1.00). There was a 
significant negative correlation between Mefloquine (MQ) and Amodiaquine (AQ) half maximal 
inhibitory concentration r=-0.25, p-value 0.04308, 95% CI (-0.4577- 0.00815) (Figure 10 & Figure 
11). There was no significance in the negative correlation between Artesunate and Artemether IC50 
values, r=-0.16, p-value 0.2, 95% CI (- 0.3821–0.08346) (Figure 10). There was also no significant 
correlation between Lumefantrine and Dihydroartemisinin drugs, r=-0.22, P-value = 0.08, 95% CI 
(-0.4317 – 0.02417). In 2013, the median IC50 for Lumefantrine was 25.02 with the Interquartile 
Range (IQR) 40.89. Piperaquine had a median value of 17.185nM, IQR 17.93 (cutoff IC50 is still 
not defined); Dihydroartemisinin had a median of 8.14nM with the IQR 12.07. The Artesunate 
median IC50 value was 7.557, IQR 10.82, while mefloquine had 9.7886nM with IQR of 10.4, and 
finally the artemether value was 4.10439nM, IQR 3.3067 (Figure 10). In 2015, Lumefantrine had 
median of 12.515nM and IQR 29.62, Piperaquine 15.48nM with IQR 19.42, Dihydroartemisinin had 
3.23 and IQR of 17.14. The Artesunate median IC50 was 7.32nM with IQR 11.09, mefloquine 
8.496nM with IQR15.01 and finally artemether had 1.90nM and IQR 9.24 (Figure 12). A significant 
difference between the two treatment arms (Artemether Lumefantrine and Artesunate Mefloquine) 
was detected, P-value 0.0005574, 95% CI (-0.09837 - 0.02822), mean of 0.2798 and 0.3431 
respectively. Using the same t-test model a significant difference between the parasite clearance slope 
half-life between the two treatment arms was observed, P- value 0.001202, 95% CI (0.1518-0.5999), 
mean of 2.598 hours and 2.222 hours respectively. The median parasite clearance half-life in the 
Artemether lumefantrine treatment arm was 2.47 (1.48-4.22) and the Artesunate amodiaquine arm 










Figure 10. Correlation between different ACT drugs, mefloquine and amodiaquine have a significant negative 
correlation. Artemether and Artesunate, Artemether and Lumefantrine, Artemether and mefloquine, 
Dihydroartemisinin and Lumefantrine did not show significant negative correlation (Pearson correlation test).  
 
Figure 11. Linear regression plot showing Spearman correlation of Amodiaquine and Mefloquine. 




Figure 12. Median inhibitory concentrations 50% for different drugs in 2013 and 2015 
3.1.2.4 Within-host population differentiation as a measure of evolution 
The parasite population on day zero hour zero (D0H0) and day 1 hour 24 (D1H24) were 
significantly different from parasites on day 35, P-value 0.0036. The Hedrick (2005) and GST 
genomic summary statistics test, which is an analogue of FST, and Jost (2008) were used to 
confirm the accuracy of FST values (see Table 3). The global population differentiation (FST) 
over all the loci was 0.0547. Global FST shows minimal population differentiation within the 
parasite population at different time points. 
Table 3 Plasmodium falciparum differentiation at different time points. Parasite population on day 
thirty-five show high population subdivision (Microsatellite Analyzer) 
Fst  pop1 pop2 pop3 pop4 pop5 pop6 pop7 pop8 pop9 
pop1 0 0.01275 0.030586 0.043308 0.041928 0.059849 0.038113 0.352825 0.037419 
pop2 0.01275 0 0.011893 0.033242 0.036035 0.07678 0.053072 0.375401 0.028065 
pop3 0.030586 0.011893 0 0.035672 0.028459 0.081685 0.079302 0.412894 0.029267 
pop4 0.043308 0.033242 0.035672 0 0.084945 0.156652 0.082283 0.508292 0.04901 
pop5 0.041928 0.036035 0.028459 0.084945 0 0.127946 0.109577 0.548673 0.080283 
pop6 0.059849 0.07678 0.081685 0.156652 0.127946 0 0.089128 0.676471 0.147101 
pop7 0.038113 0.053072 0.079302 0.082283 0.109577 0.089128 0 0.415424 0.103548 
pop8 0.352825* 0.375401* 0.412894 0.508292 0.548673 0.676471 0.415424 0 0.50158 





Figure 13. Pairwise Gst, G'st and Jost's D population differentiation estimates. 
 
Figure 14. Within-host population differentiation FST values. Pop1 (H0D0), pop2 (D1H24), pop3 (D2H30), 






3.1.2.3.0 Within-host allele frequency calculation  
A total of one hundred and twenty-five P. falciparum parasites were used in the analysis. 
Parasites were grouped according to the treatment time points from day zero, hour zero to day 
forty-two, giving a total of nine populations (pop1-pop9). A total of 12 microsatellites were 
analyzed (microsatellite chromosome location in parenthesis) and they include the following: 
2490 (10), ARA2 (11), PFG377 and Pfk2 (12), poly alpha (4), TA 81 (5), TA1 and TA 87 
(6), TA60 (13), TA40 (10), TA108 (6), TA42(5). The range of alleles per locus was between 6 
and 28. Locus poly alpha had the highest Simpson diversity (0.91) and ARA2 had the most 
evenly distributed alleles (0.86). TA40 had the lowest expected heterozygosity (0.42) while poly 
alpha locus had the highest expected heterozygosity (0.91) as shown in Table 4. 
Table 4: Allele frequency distribution across 12 microsatellite loci. 
Locus  Allele  Genetic Diversity  He  Evenness  
2490  10.00    0.66    0.67       0.55  
ARA2  6.00    0.73    0.73       0.86  
PFG377     8.00    0.65    0.65       0.67  
PFpk2  10.00  0.82  0.82  0.73  
Poly alpha  28.00  0.91  0.91  0.66  
TA109  14.00  0.87  0.88  0.83  
TA40  16.00  0.43  0.43  0.34  
TA42  12.00  0.52  0.52  0.45  
TA60  13.00  0.86  0.86  0.81  
TA87  14.00  0.58  0.59  0.43  
TA1  18.00  0.90  0.90  0.83  













Figure 15. Discriminant Analysis of Plasmodium falciparum parasites at different time points 
We then did the discriminant analysis of the principle components (Jombart et al. 2010), to 
visualize how different parasite populations cluster in space during the treatment course as 
shown in (Figure 15, Figure 18 and Figure 19). It was evident that the first two discriminant 
analysis eigenvalues explained the data better and they are labelled in black (Figure 15). From 
the results (see Figure 15) it is evident that the parasite population in day 35 (pop8) is more 
distinct genetically from other parasite populations because they cluster separately. It is 
imperative to look at the alleles that most differentiate these parasite population from the other 
parasites. From Figure 16, it can be seen that alleles at the microsatellite loci poly alpha 
(chromosome 4) and TA81(chromosome 5) are involved in differentiating the parasite 
populations at day 35 (pop8).In Figure 16, we determined the microsatellite loci which were 
highly polymorphic and how they contribute to the parasite clustering in space. We found that, 
Poly alpha and TA81 loci are highly polymorphic. The allele richness analysis (Figure 20 and 
Figure 21) confirmed that the P. falciparum from Kombewa and Maseno are still sensitive to 
ACT drugs. This is due to a rapid decrease in the parasite population from day one to day forty-
two during the treatment period (see Figure 20 and Figure 21). There were variations in SNPs 
over the twelve microsatellite loci during the treatment course and this did not follow a clear 
pattern (Figure 17). This could be due to differences in the immune response during treatment. 
It was evident from our analysis that the clearance slope half-life does not correlate with the 




Figure 16. Loading plot showing why parasites on day thirty-five (pop8) are distinct from the other parasite populations 
within the host. 
The evolutionary effect of the two loci, Poly alpha and TA81 across the entire Plasmodium falciparum 
population during treatment was determined (Figure 17).  
 
Figure 17. Evolutionary effect of poly alpha and TA81 loci. Allele variation over the two loci, Poly alpha and TA81 
from day zero to day forty-two. The parasite populations at different time points were treated as distinct parasite 






Figure 18. Discriminant Analysis of Principle Components (DAPC) plot of within-host parasite populations at 
different time points. 
 
 
Figure 19. Discriminant Analysis Principle Components analysis. This analysis shows distinct 











Figure 21. Plasmodium falciparum allele richness variation over time. Parasites on day zero hour zero have the 
highest allele richness, meaning they have high evolvability potential compared with the other parasite 




Figure 22. Kelch 13 maximum likelihood phylogenetic tree, the parasite evolution clustering is stochastic since 




Phylogenetic analysis (see Figure 22) was done and the main motivation was to understand the 



























Chapter 4. Discussion 
4.1 Neutral models of evolution 
Adaptive evolution to artemisinin combination therapy regimen can be studied using genotypic and 
Ring Stage Survival Assay (RSA0-3hr) methodologies. ACT resistance is evident when there is an 
increase in parasite clearance slope half-life which is associated with the reduced susceptibility to ACT 
drugs in vitro (Ariey et al. 2014), resulting in ACT treatment failure. In Kombewa and Maseno, which 
are high transmission settings in Kisumu County, Kenya, there is a large usage of artemisinin drugs 
throughout the year. A study by Watsierah et al (Watsierah et al. 2011) in Kisumu peri-urban settings 
found that only 29.4 % of the study population used the right ACT drugs to treat malaria infection 
(Watsierah et al. 2011). Patient behavior such as non-adherence to ACT drug and individual 
variations may provide room for the parasites to evolve and become non-responsive to treatment. 
When poor-quality drugs are prescribed to the patients, it results in low bioavailability, making the 
drugs unable to exert their therapeutic effects, hence promoting the development of drug resistance 
(Maponga and Ondari 2003). A study carried out by Akulayi et al in Africa found that 20% of non-
quality assured Artemisinin Combination Therapy drugs (non-QAACT) are in circulation in the 
Kenyan markets, contrary to the World Health Organization quality assurance recommendations 
(Akulayi et al. 2017; Maponga and Ondari 2003). Musuva et al reported that only 58.2% of the drugs 
in circulation satisfy WHO quality assurance standards (Musuva et al. 2017). These statistics are of 
great concern noting that the use of substandard drugs in South East Asian countries is the main driver 
of drug resistance development. Kenyan P. falciparum populations may also evolve and become non-
responsive to these counterfeit ACT drugs. 
Kenya adopted ACT in treatment of non-severe malaria in 2006 and it has remained efficacious since 
its adoption (Amin et al. 2007). The World Health Organization report indicates an increase usage 
of ACT in Sub-Saharan Africa and tropical regions of the world between 2006 and 2015 (World Health 
Organization 2016, 2015c). As a malaria holoendemic setting in Kenya (Bejon et al. 2010, 2014), an 
increase usage of ACT drugs has a possibility of raising drug pressure and thus the risk of adaptive 
evolution of P. falciparum parasites to these drugs (Ocan et al. 2016). Therefore, the neutrality model 
of evolution was used to determine the departure of Kelch 13 nucleotide sequences from neutral 
evolution using Tajima’s D, Fu & Li F*, and Fu & Li D* genomic summary statistics tests (Tajima 
1989; Fu and Li 1993). In 2013, the P. falciparum Kelch 13 gene was found to be under balancing 
selection (see Figure 4) as shown by significant positive values of Tajima’s D. These 2013 finding 
were consistent with results from Oyebola et al study conducted in Nigeria in 2013, which showed 
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that P. falciparum isolates were under balancing selection. The findings are an indication that African 
parasites might be behaving the same in the presence of ACT drugs (Oyebola et al. 2017). However, 
there was also an evidence of selective sweeps (positive selection) as shown by significant negative 
test values observed from 2015 Kelch 13 nucleotide sequences (Figure 4). 
Our findings using the 2015 Kelch 13 sequence data is consistent with results of a previous studies 
conducted in Uganda by Ocan et al (Ocan et al. 2016) and in the Gambia by Amambua- Ngwa et al 
(Amambua-Ngwa et al. 2012), in which P. falciparum was shown to be under selective sweep (Ocan 
et al. 2016; Amambua-Ngwa et al. 2012). This is an indication that the African P. falciparum 
parasites are gaining fitness potential to be able to survive under ACT treatment nine years after ACTs 
were adopted as the first line treatment of uncomplicated malaria in most African countries, including 
Kenya (Ministry of health 2012). 
The prevalence of non-synonymous single nucleotide mutations which are beneficial to P. falciparum 
were on the rise during our study and this may be attributed to the effects of an increase drug pressure. 
The lack of adherence and an improper usage of antimalarial drugs are thought to be the main causes 
of the adaptive evolution to ACT drugs in malaria parasite population (Watsierah et al. 2011). For 
decades, P. falciparum proteins have been shown to be enriched in non-globular domains whose 
functions remain unknown. These protein domains, including the Kelch 13 propeller domain, have a 
high potential for undergoing genetic drift and thus provide a big challenge in the attempts to 
determine the molecular dynamics of adaptive evolution in P. falciparum parasites (Gardner et al. 
2011). Our finding using nucleotide sequences was consistent with the amino acid sequence analysis 
of Li et al. conducted in Lira and Gulu, in Northern Uganda (Li 1993), which showed that in 2013 
P. falciparum was under balancing selection. The codon-by-codon evolutionary pattern along the 
Kelch 13 (pfk13) gene changed exponentially between 2013 and 2015, which increased the 
evolutionary potential of these parasites to resist ACT drugs. This research could not explicitly 
explain whether mutations in the PF3D7_1343700 gene in P. falciparum from Kisumu were due to 
transfer through global human travel or local emergence due to parasite population level processes. 
A total of seventeen non-synonymous single nucleotide polymorphisms were detected in P.  
falciparum parasites from Kisumu (Table 2). Some of these seventeen SNPs in the Kelch 13 propeller 
domain may be associated with drug resistance development as was demonstrated by Njoka et al 
(Njokah et al. 2016). The two predominant non-synonymous SNPs in our data were D559E which 
was present in 42/ (61.76%) of the samples and D547E which existed in 37/ (54.41%) of the samples. 
These non-synonymous mutations are specific to Kenyan parasites and have not been reported in any 
other African country or South-East Asia countries (Ocan et al. 2016; Ariey et al. 2014). The Kelch 
13 propeller domain is highly conserved in Plasmodium and even though its exact function has not 
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been determined, it is thought to be involved in protein-protein interactions. The World Health 
Organization officially included the following non-synonymous single nucleotide mutations: Y493H, 
I543T, R539T, C580Y and M476I in the PF3D7_1343700 gene in tracking ACT drug resistance in 
August 2014 (Njokah et al. 2016). In our research, the mutations reported elsewhere were not detected 
and there was no signal of reduced susceptibility to ACT in the Kenyan P. falciparum populations. 
Artemisinin resistance due to ACT drug pressure has not been reported in Africa, but SNPs which are 
not associated with treatment failure are present as observed in several studies (Daniels et al. 2008; 
Sisowath et al. 2005). Since Myanmar is centrally located between Africa and South East-Asia, and 
resistance to ACTs has been reported in this region, it is feared that these resistant parasites may gain 
entry to Africa following the chloroquine resistance path of the 1960s (Roper et al. 2004). 
Periodic tracking of these genetic markers of ACT drug resistance is of great importance in controlling 
the spread of drug resistance to Sub-Saharan Africa. P. falciparum parasites in 2013 showed low level 
of variability with the haplotype diversity (Hd) and nucleotide diversity (π). In 2015, P. falciparum 
parasites showed a higher level of diversity and the nucleotide diversity. The high variability between 
the two-time points was consistent with the findings in a study conducted in Malawi by Ocholla et al 
2014, where high genetic diversity of the parasite population was detected during treatment, a 
characteristic associated with the African parasites, especially in the regions of high malaria 
transmission (Ocholla et al. 2014). A study conducted by Feng et al (Feng et al., 2015) found SNPs 
at codons 537 and 574 in the Kelch 13 gene in P. falciparum strains which infected Ghanaian migrants 
to the Republic of China. These mutations have also been reported in Cambodian P. falciparum 
parasite strains (Ocan et al. 2016). The findings in this research, in addition to Feng et al’s results in 
Ghana, and other Sub-Saharan countries (Feng et al. 2015), is an indication that ACT drug resistance 
is likely to be reported among P. falciparum parasites from Africa soon. 
Recent studies carried out in Kenya and Uganda (Achieng et al. 2015; Cooper et al. 2015), in addition 
to other regions of Sub-Saharan Africa, specifically in the Republic of Mali, West Africa (Ouattara et 
al. 2015), and Myanmar (Tun et al. 2015), found non-synonymous point mutations in P. falciparum 
which have not been reported in Cambodia (Ariey et al. 2014). Geographic differences in Kelch 13 
propeller gene point mutations indicate the presence of a global reservoir for the Kelch 13 propeller 
gene (Ocan et al. 2016). However, whether these SNPs are associated with the increased parasite 
clearance slope half-life needs to be investigated further, as it will help in understanding ACT 




4.2 IC50, Slope-half life and SNP association analysis 
In this research, we determined that in 2013 there were no non-synonymous point mutations after 
mapping and visualizing the mapped reads to the reference Kelch 13 reference gene sequence using 
Artemis (Carver et al. 2012). Due to a lack of non-synonymous point mutations from the 2013 
SNPArray data, we did not carry out the association analysis of parasite clearance slope half-life, and 
IC50s with the SNPs. There was no significant association between SNPs and parasite clearance slope 
half-life which was consistent with the report by Ngala et al in 2013 (Ngalah et al. 2015) in samples 
from Kisumu County. Seventeen non-Synonymous SNPs were present in the P. falciparum genome in 
2015 samples. There was a significant association between IC50 and the SNP at codon D559E with 
Amodiaquine (AQ) and Mefloquine (MQ). Codon D547E also had a significant association with the 
Artesunate half maximal concentration. 
These data reveal a sharp increase in non-synonymous point mutations between 2013 and 2015 in 
Kenyan P.  falciparum parasites. Previous studies using P. falciparum parasites from Africa and 
South-East Asia have found a 35 kilobase locus on chromosome 13 to be associated with the reduced 
parasite clearance rate, an indication that it plays a role in ACT drug resistance (Cheeseman et al. 
2012; Ngalah et al. 2015; Amato et al. 2017). Lack of non-synonymous point mutations from the 
Kenyan P. falciparum parasites may be explained in part to the reduction of pressure following the 
withdrawal of chloroquine and Sulphadoxine-pyrimethamine as the first line treatment of 
uncomplicated malaria in 2006 (Watsierah et al. 2011). Candidate genes on chromosome 13 such as 
the Kelch 13 gene, lipoate synthase, and hsp70 and many more conserved genes whose functions are 
not well understood have been implicated in the development of drug resistance in P. falciparum 
(Ouattara et al. 2015). Resistant parasites from SEA have a high frequency of mutations in pfk13 and 
these mutations have shown significant association with the delayed parasite clearance during 
treatment (Cheeseman et al. 2012). 
The two SNPs, D557E and D559E, as Y493H, I543T, R539T, C580Y and M476I which were 
reported by Ariey et al (Ariey et al. 2014), may be considered as the potential treatment failure markers 
in Kenyan parasites. Since these two SNPs, D557E and D559E occur at a higher frequency in our 
samples, we alluded that they may be the potential markers for drug resistance in the Kenyan P. 
falciparum. Further research needs to be done to validate this finding. It is interesting that a significant 
association in in vitro drug susceptibility and SNPs was detected in the Kenyan P. falciparum parasite 
in our study, and it may be a wakeup call for surveillance of ACT drug resistance, since such 
molecular findings have been used previously to determine drug administration policy in Tanzania 
(Mugittu et al. 2004). 
The results in (Figure 12) from two different time points show that the Kenyan parasites are still 
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sensitive to ACT drugs even though the non-synonymous point mutations are on the rise due to 
adaptive evolution. The same observations have been reported in Mali by Ouattara et al (Ouattara et 
al. 2015), in Uganda by Cooper et al (Cooper et al. 2015) and in Kenya by Ngala et al (Ngalah et al. 
2015). 
Drugs with correlated modes of therapeutic effects indicates related mode of action. Most importantly, 
drugs with significant negative correlations may reveal synergistic partner drugs which can be 
deployed in population on a rotational basis (Wendler et al. 2014). There was a significant negative 
correlation between Mefloquine (MQ) and Amodiaquine (AQ) half maximal inhibitory 50% 
concentration. Artesunate and Artemether modes of action were negatively correlated without 
reaching while there was no significant correlation between Lumefantrine and Dihydroartemisinin. 
Interestingly, this was consistent with a study done in Kenya by Wendler et al 2014, in which they 
found that piperaquine was significantly correlated with the amodiaquine. The mean parasite 
clearance slope half-life was less than three hours compared with Cheeseman et al (Cheeseman et al. 
2012) report, where the parasite clearance slope half-life was more than five hours. These findings 
are expected in part because Kenyan parasites are still sensitive to ACT drugs. The finding also 
mirrors the Ngalah et al report which showed that P. falciparum from Western Kenya are still 
sensitive to ACT. 
4.3 Within-host population differentiation as a measure of evolution 
The change in malaria treatment and control policies in Kenya in 2006 (Watsierah et al. 2011), where 
artemisinin derivatives were adopted for the treatment of uncomplicated malaria, was a major 
achievement in the fight against malaria in Kenya. Interestingly, when these drugs were being 
introduced in Kenya, resistance to these drugs was already evident in Cambodia (Noedl et al. 2008). 
ACT drugs impose a strong selective pressure on the P. falciparum genome, altering parasite genomic 
structure.  This analysis was aimed at evaluating the changes in P. falciparum parasite population 
genetic diversity and differentiation at different time points during ACT treatment. The analysis 
further looked at the temporal changes in P. falciparum parasites from day zero to forty-two within 
the human host. There was moderate parasite population structure differentiation (Figure 13) between 
the parasite populations within host, except for day thirty- five parasites, which were significantly 
different from day one parasite populations (Table 3). 
The lack of significant genetic differentiation is consistent with findings (Ouattara et al. 2015) on 
African parasites which are still sensitive to ACT drugs. These drugs still neutralized P. falciparum 
within the human host as expected, since no ACT resistance has been reported from Kisumu P. 
falciparum parasites. The (unique parasite population from day 35 may be explained in part to 
superinfection. Patients on day thirty-five might have been infected by parasites with different genetic 
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background, and since we did not have the meta data on the migration history of these patients but 
hypothesis that these unique parasites having a different genetic background may have been 
introduced in this population due to human migration into the Kombewa. Druilhe and his colleagues 
(Druilhe et al. 1998) demonstrated that a single mosquito bite (Figure 2) may deposit a large amount 
of malaria parasites in the human blood stream which may have different genetic diversity. In 
addition, Zhong et al in their study using the same microsatellite data also found that the parasite 
population from Western Kenya had a significantly high genetic differentiation which was attributed 
to human migration (Zhong et al. 2007). This may explain the distinct parasite difference on day 
thirty-five, although it does not explain why this dropped again after day 35. 
Selective pressure due to ACT usage results in unique genetic signatures of P. falciparum population 
structure within the host. The expected heterozygosity in our data was much higher compared with 
data from Columbia, Brazil and Bolivia with expected heterozygosity ranging between 0.30-0.40. 
There was high genetic diversity of P. falciparum during the treatment period, which was attributed 
to high malaria transmission in Kombewa and Maseno. Within host genetic differentiation was 
moderate, an indication of gene flux in this parasite population. This observation is consistent with 
Nabet et al’s finding in Mali, where the parasite populations displayed high genetic diversity and 
moderate population differentiation during ACT treatment (Nabet et al. 2016). In Thailand, P. 
falciparum parasites had an expected heterozygosity value of 0.51 (Anderson et al. 2000), but our 
finding was consistent with the joint studies carried out in African Countries: Cameroon, Ghana, 
Uganda, Gambia and Benin, where expected heterozygosity was 0.69 (Durand et al. 2003). Genetic 
diversity in our P. falciparum data was much higher during the treatment with only locus TA40 
harboring a genetic diversity parameter below 50% (Table 4). Zhong et al (Zhong et al. 2007) found 
that the poly alpha loci across the entire parasite population had the highest number of alleles in their 
study and our results also show the same pattern. In Congo and Zimbabwe, the studies show that the 
expected heterozygosity of P. falciparum higher (0.76-0.80) during ACT treatment, but the parasites 
remain sensitive to ACT drugs. These findings are comparable with our result (Table 4). Interestingly, 
Vardo-Zalik and colleagues (Vardo-Zalik et al. 2013) also observed high genetic diversity (He = 
0.74) in P. falciparum from Kombewa after the ACT intervention and the scale up of insecticide 
treated bed nets (ITNs) usage in western Kenya. Our data also shows the same pattern with the high 
genetic diversity values seen across all the twelve microsatellite loci (Table 4). This may have a large 
implication as it may result in an increase in parasites which may soon become non-responsive to ACT 
drugs in our population. The two microsatellite loci: Poly alpha and TA81 (Figure 16) are the main 
molecular markers that contribute most to the differentiation of the P falciparum parasites and 
specifically on day 35 (pop8). Day thirty-five parasites were expected to be similar to day zero-hour 
zero parasite populations which was not observed in our data. Since we did not have these patients’ 
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metadata, we hypothesized that these patients may have been infected with a parasite with a different 
genetic background. This is indicative of high polymorphism rate in those two microsatellite loci. The 
allele variation over these loci at different treatment time points from day zero, hour zero pop1 to 
pop_9 (day 42) is considerable and does not follow a clear pattern (Figure 17). A study conducted in 
Guinea by Murray and colleagues to identify the genetic diversity using P.  falciparum clinical 
isolates found that the polymorphisms on these microsatellite loci are not uniform (Murray et al. 
2016). These findings are comparable with our result where there was a stochastic variation of alleles 
over these two loci at different time points during treatment with the highest frequency reached in 
population 8 (Figure 17). Irrespective of the process underlying these diversities (selection or genetic 
drift), it is an illustration that in P. falciparum, specific non-synonymous point mutations may occur 
in the genome within a short period of time during treatment. 
Hierarchical clustering of parasite populations is an important tool in the study of parasite evolution 
within the human host over time. As revealed by the Discriminant Analysis of Principle Component 
(Jombart et al. 2010), P. falciparum “populations” demonstrated distinct clustering from population 
1 to population 9 (Figure 18 & Figure 19), the parasite populations were primarily clustered in nine 
and five groups, during the treatment course. In Figure 19, P. falciparum showed distinct clustering 
according to the treatment time points. The P. falciparum in our study have been shown to have a 
high parasite genetic diversity (see Table 4), this explains why some parasites did not undergo 
evolution and their genome contents did not change over the treatment course. This is evidenced by 
the overlapping of the points from one population to the other in the Discriminant Analysis of 
Principle component plots (Figure 19). Another plausible explanation for the overlapping of these 
parasite strains in space can be attributed to the moderate parasite population differentiation during 
treatment course owing to the fact that Kisumu is a high malaria transmission zone (Sifuna et al. 
2014). P.  falciparum from Kisumu are still sensitive to artemisinin derivate (Ngalah et al. 2015) 
drugs and this is shown by the rapid parasite population decline during ACT treatment. Analysis of 
the microsatellite data provides a prime basis on which we can discriminate parasite populations at 
different time points, but a lack of power for discriminating clonal from non-clonal infections and 
distinction of different parasite strains from each other is very difficult. The rapid neutralization and 
the sensitivity of P. falciparum to ACT drugs was evident due to a sharp decrease in the allele richness 
during the treatment (Figure 20 & Figure 21). Allele richness has a direct correlation with the 
population under study and the sharp decrease in the allele richness in this study confirmed that these 
drugs are still efficacious. A rapid decrease in the allele richness over time reduces the evolvability 




4.4 Evolutionary effects of mutations on Kelch 13 propeller domain 
The Kelch 13 propeller domain is made up of six blades (Figure 6) consisting of protein-protein 
interaction sites. Mutations occurring in the β-sheet sites may hinder effective K13 protein-protein 
interactions with other protein molecules. Mutations in the Kelch like proteins have been linked with 
the development of hypertension in humans (Boyden et al. 2012). The P.  falciparum PI3K is 
assumed to be the binding partner of Kelch 13 and it is the main protein molecule being targeted by 
ACT drugs (Boussaroque et al. 2016). When ACT drugs bind to the phosphatidylinositol 3 Kinase 
(PI3K) protein, its kinase activity is reduced significantly, thus reducing phosphatidylinositol-3- 
phosphate (PI3P) biochemical activity, and parasite growth is inhibited. Non-mutant Kelch 13 binds 
PI3K and marks it for ubiquitin ligase, which facilitates the ubiquitination process of Kelch 13, a 
marker for degradation by proteasome enzymes (Boussaroque et al. 2016). This biochemical process 
cannot be facilitated by mutant Kelch 13 protein because it does not bind PI3K. Our predicted Kelch 
13 propeller domain model (Figure 6) was consistent with findings in Senegal by Boussaroque et al 
(Boussaroque et al. 2016), results from South East Asia by Ariey et al (Ariey et al. 2014) and data 
from Boyden et al (Boyden et al. 2012) model of human kelch like propeller domain. 
Mutations occurring in structural genes are the main drivers of evolution as they may introduce 
diversity into the organism’s genome and proteome, and this occurs mostly through non-synonymous 
point mutations (Pires et al. 2014). Non-synonymous mutations result in changes of amino acids and 
are of interest because they interfere with the natural conformation of the protein, hence potentially 
reducing stability or interaction of the protein with other protein molecules. These mutations can 
favor selection during the evolutionary course and render functional proteins non-functional by either 
reducing or increasing their stability (Pandurangan et al. 2017). 
Intra and inter-blade hydrogen bonding in a mouse Kelch-like ECH associated protein 1 (keap1) 
domain maintains the structure and ensures effective interaction with keap1 and Nrf2 “regulator of the 
cellular oxidative stress response”. Non-synonymous mutations are associated with development of 
human cancer because these mutations, change the native structure of keap1, hence reducing the keap1 
association with the Nuclear factor erythroid 2-related factor 2 (Nrf2) (Padmanabhan et al. 2006). In 
P. falciparum, evolutionary forces affecting the protein targeted with drugs may result in the 
development of non-responsive parasites to ACTs drugs. We found that most of the non-synonymous 
mutations occurring in P. falciparum in 2015 were associated with reduced stability of the Kelch 13 
propeller domain (Table 1). The reduced stability of the Kelch 13 propeller domain may be causing 
a change in the local conformation of the protein hence affecting its activity, resulting in the 
development of parasites which are insensitive to ACT drugs but they remain responsive to treatment. 
This finding is consistent with a study done by Gardner et al (Gardner et al. 2011), which showed 
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that non-synonymous point mutations in P. falciparum structural genes cause adaptive evolution 
(resistance) to ACT drugs. The mutation at codon R561P causes a stabilization of the Kelch 13 
propeller domain and this can be explained in part to the introduction of a kink by a proline amino 
acid, which increases the folding of the domain. 
The change in the Gibbs free energy score infers the effect of non-synonymous point mutations by 
predicting the energy difference between wildtype and the mutant protein molecule which predicts the 
functional consequence of the mutation (Pandurangan et al. 2017). These mutations, just like other 
point mutations occurring on structural proteins, are thought to modulate the Kelch 13 protein function 
and affect its interactions with other proteins as well as drug molecules. Even though the “Pan African” 
SNP (M476I) (Torrentino-Madamet et al. 2014) selected in parasites in vitro was not detected in our 
samples, it is also thought to affect the Kelch 13 propeller domain local conformation. P. falciparum 
and its disease progression within-host is the product of protein interactions between P. falciparum 
and the human host. 
P. falciparum is a threat to life in the tropics (Figure 1) this is due to its high potential for developing 
resistance to already available antimalarial drugs and its evolutionary dynamics in nature (Saha et al. 
2017). Paloque et al. (Paloque et al. 2016) also found that P. falciparum adaptive evolution to ACT 
drugs is due to escalated counts of young ring forms of parasites which enter quiescence when they 
come into contact with artemisinin and immediately continue growing when the artemisinin drug 
pressure is withdrawn. The ability to undergo quiescence is made possible to a non-synonymous point 
mutation in the Kelch 13 propeller domain which is the main target of the ACT drugs. Figure 7 and 
Figure 8 show the Kelch 13 proper ACT binding pocket and ACT/k13 interaction respectively. 
Interestingly, these predictions reveal the hypothetical active site of Kelch 13 which is predicted to be 
on chain A. This explains why the non-synonymous point mutations are mainly located on the intra 
or inter-blade domains on the Kelch 13 protein (Amato et al. 2017; Feng et al. 2015). Kelch 13 
propeller domain modelling data indicates that most of these mutations increase the relative side chain 
solvent accessibility in the mutant protein structure (Table 2). This result is in agreement with the 
Mohon et al (Mohon et al. 2014) findings in Bangladesh where non-synonymous mutations were 
shown to change the local conformation of the Kelch 13 propeller domain. L571S, which is associated 
with the highest destabilization effect in our data (Table 1) on the pfk13 propeller, was closest to the 
SNP at codon C580Y (Figure 6), the main point mutation occurring at high frequency in the 
Cambodian P falciparum strains (Ariey et al. 2014). Of great importance is the position of these 
mutations, all of them lie after SNP position 400 and this may have a significant effect on Kelch 13 
structure and hence may affect the ACT drug activities. Mutations in our data all occurred after 
position 400 on Kelch 13 propeller domain and this was consistent with the Paloque et al’s findings 
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which showed that most mutations occurring after position 400 are non-synonymous and some of 
them are strongly associated with ACT resistance (Paloque et al. 2016). Measures such as parasite 
clearance slope half-life and P. falciparum clearance rate are multifactorial “phenotypes” which may 
be affected by the host immunity, drug metabolism or pharmacokinetics and the patient adherence to 
ACT drugs during treatment (Mohon et al. 2014). Increased parasite clearance slope half-life has been 
documented in Bangladesh even though mutations in the Kelch 13 propeller domain have not been 
reported which may be explained by the multifactorial effects of within host dynamics mentioned 
(Mohon et al. 2014). In Africa, mutations have been reported in the Kelch 13 propeller domain but 
the ACT drugs remain efficacious in treatment of malaria in Sub-Saharan Africa (Ouattara et al. 
2015). 
  
4.5 Plasmodium falciparum Kelch 13 phylogenetic tree construction 
Evolution of P. falciparum within the human host can be described as a “tree evolving inside another 
tree” (Sennblad et al. 2007). As humans evolve, the parasite also undergoes evolution which, in this 
case, is promoted by high ACT drug pressure within the human host. Sporadic adaptation of 
organisms to new environmental conditions or stress has been described in a variety of proteins, 
including stomach proteins in primates, sperm proteins of invertebrates and the variation of bacterial 
surface proteins (McInerney et al. 2003). These adaptive changes have led to the lifestyle changes 
and speciation among these organisms from which these changes have been described (McInerney et 
al. 2003). From our findings, it is evident that a positive selection has occurred in the P.  falciparum 
kelch 13 gene (Figure 4  & Figure 5) showed the identified amino acids at codon D559E and D547E 
which may be the main drivers of adaptive evolution in our P. falciparum population in response to 
ACT drugs. From the Maximum likelihood (Yang 2000) phylogenetic tree (Figure 22), it is 
interesting to note that over 25.32 % of our sequences are showing evidence of positive selection 
which drives change in P. falciparum to become non-responsive to ACT treatment. This is because 
they are evolving faster due to intense drug pressure. The positive selection observed may be explained 
in terms of their location on the Kelch 13 domain; where they are on chain A or Chain B. Amino acids 
sequences found on chain A are expected to undergo positive selection faster compared with the 
amino acid sequences on chain B (Figure 8). The reason being that, it is chain A which is predicted to 
contain the active site where ACT drugs are thought to be interacting with the Kelch 13 propeller 
domain. Based on the phylogenetic analysis of the Kelch 13 sequences, it is not easy to explain the 
differential appearances of selective pressure in different P.  falciparum isolates within the human 
host, however this may be attributed to differential interaction of P. falciparum with the human host 
immune system. The human immune system works differently and individuals may illicit different 
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immune responses during infections as was observed by Hastings et al (Hastings, Kay, and Hodel 
2015). 
However, in a previous study conducted by Maeno et al (Maeno et al. 2017) in Vietnam, they 
demonstrated that the evolution of P. falciparum isolated from the mosquito salivary gland is much 
slower compared with the human host. This could be because within the mosquito host the parasites 
are free from the immune attack hence no immune pressure unlike in human where they face both the 
drug and the immune pressure. Parasite clearance slope half-life is a stochastic event as it varies from 
parasite to parasite (see Figure 22) and parasites with the same clearance slope half-life may have 
different evolutionary rates. Most of non-synonymous polymorphisms were present at low frequency 
and they were specific parasite strains, an indication that they might be transitory point mutations 
which may be attributed to ACT drug pressure or natural evolution. This explains why most parasite 
strains have a lower evolution rate and they cluster together in the phylogenetic tree (Figure 22). This 
result is consistent with Talundzic et al’s finding in Senegal where they attributed the transient 
occurrence of non-synonymous mutation to natural evolution due to ACT usage on Senegalese P. 


















Chapter 5. Conclusions and Recommendations 
5.0 Conclusions 
In this dissertation, we set out to investigate the evolutionary changes in the P. falciparum genome 
due to Artemisinin Combination Therapy (ACT) intervention in Kenya between 2013 and 2015. Our 
data suggests that P. falciparum in Kenya still lacks previously known non- synonymous point 
mutations such as Y493H, I543T, R539T, C580Y and M476I, which have been associated with the 
increased parasite clearance slope half-life in Cambodia and other locations in South East Asia. The 
“Pan African SNP” M476I which was selected in parasites in vitro across Africa was not detected in 
our samples. However, non-synonymous point mutations at codon D559E and D547E are present at 
high frequency in our samples and affect the local conformation and the native structure of the Kelch 
13 propeller domain by destabilizing the protein structure. These two SNPs showed significant 
associations with the IC50s of AQ, MQ and Artesunate but these ACT drugs were still efficacious in 
Kenya. The samples from the Kombewa and Maseno divisions, which are in a malaria holoendemic 
region in Western Kenya showed a high variation in parasite clearance slope half-life, which was 
expected in part since different P. falciparum parasites have different genetic makeup.  
Parasites from Kisumu are under positive selection an indication that these parasites are gaining 
fitness in the presence of ACT and soon they may become non-responsive to these drugs as happened 
with CQ. In this study a total of seventeen non-synonymous single nucleotide polymorphisms were 
detected and none showed significant association with the increased parasite clearance slope half-
life. 
P. falciparum clearance slope half-life time in Kenya is still in the low range (2.22-2.60 hours), 
compared with Cambodian and Myanmar parasites which take more than 6.2 hours to be cleared. We 
also found significant negative association between mefloquine   and amodiaquine which may be 
used in our population on a rotational basis to avoid the simultaneous development of adaptive 
evolution to resistance against these drugs. Population subdivision of P. falciparum within the human 
host showed minimal population differentiation of P. falciparum during treatment. In a span of forty-
two days, we found parasites with a distinct genetic make-up which is due to the adaptive evolution 
of these parasites. There was a limitation in the understanding of the evolutionary effects of the P. 
falciparum Kelch 13 gene due to ACT usage. In this dissertation we demonstrated clearly that the 
Kenyan parasites are becoming more fit in the presence of ACT even though they are still susceptible 
to ACT treatment. Microsatellite data shows that these parasite populations are highly polymorphic 
having a high potential for adapting within the host to impede ACT intervention. Low population 
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differentiation implies that resistant parasites may spread easily from one region to the other, which 
makes malaria control at the local level inefficient. 
5.1 Recommendations 
The adaptive evolution on the P.  falciparum Kelch 13 propeller domain is very high due to a rapid 
increase in non-synonymous mutations, which increases the potential of Kenyan P. falciparum to 
increase its fitness in the presence of ACT drugs. We recommend regular molecular surveillance of 
this lethal parasite to determine novel SNPs which will point us in the right direction in the fight against 
malaria in Kenya. An accurate diagnosis of malaria infection is needed before the right dosage 
prescription of ACT drugs is delivered. 
The statistics on the supply and use of counterfeit drugs from both the private and public sector is 
worrying and quality assurance checks need to be enhanced to avoid the used of these low-quality 
drugs (Musuva et al. 2017; Akulayi et al. 2017). We recommend that the Kenya Bureau of standards 
should ensure that both public and private health facilities prescribe drugs which satisfy the World 
Health Organization quality standards (Maponga and Ondari 2003) for use in the treatment of P. 
falciparum malaria in the population. The pharmaceutical industries should be under surveillance to 
ensure that they adhere to the Good Manufacturing Practice (GMP) guidelines when making these 
antimalarial drugs. 
We recommend the continuous surveillance of the molecular markers that might correlate with the 
ACT drug resistance development by tracking the travel history of the patients visiting health facilities 
with P. falciparum malaria infections. This will inform the treatment and intervention strategies as 
resistant P. falciparum malaria may follow the path of chloroquine resistance (Ashley et al. 2014; 
Molina-Cruz et al. 2016). Effective use of ACT drugs in our populations should be encouraged as it 
will lead to a fast neutralization of the P. falciparum parasites within the host, hence derailing the 
development of drug resistance. 
Accurate information must be made available to the consumers as it will ensure the current ACT 
usage and cure rate is maintained in Kenya (Watsierah et al. 2011). The policy makers should ensure 
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